2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes: Executive Summary

Ezra A. Amsterdam, MD, FACC, Chair, Writing Committee Nanette K. Wenger, MD, MACC, FAHA, Vice Chair, Writing Committee Ralph G. Brindis, MD, MPH, MACC, FSCAI, Writing Committee Member Donald E. Casey Jr., MD, MPH, MBA, FACP, FAHA, Writing Committee Member Theodore G. Ganiats, MD, Writing Committee Member David R. Holmes Jr., MD, MACC, Writing Committee Member Allan S. Jaffe, MD, FACC, FAHA, Writing Committee Member Hani Jneid, MD, FACC, FAHA, FSCAI, Writing Committee Member Rosemary F. Kelly, MD, Writing Committee Member Michael C. Kontos, MD, FACC, FAHA, Writing Committee Member Glenn N. Levine, MD, FACC, FAHA, Writing Committee Member Philip R. Liebson, MD, FACC, FAHA, Writing Committee Member Eric D. Peterson, MD, MPH, FACC, FAHA, Writing Committee Member Marc S. Sabatine, MD, MPH, FACC, FAHA, Writing Committee Member Richard W. Smalling, MD, PhD, FACC, FSCAI, Writing Committee Member Susan J. Zieman, MD, PhD, FACC, Writing Committee Member

PII: S0735-1097(14)06278-0
DOI: 10.1016/j.jacc.2014.09.016
Reference: JAC 20607

To appear in: Journal of the American College of Cardiology


This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Developed in Collaboration With the Society of Thoracic Surgeons

Endorsed by the American Association for Clinical Chemistry

WRITING COMMITTEE MEMBERS*

Ezra A. Amsterdam, MD, FACC, Chair†
Nanette K. Wenger, MD, MACC, FAHA, Vice Chair++
Ralph G. Brindis, MD, MPH, MACC, FSCAI†
Donald E. Casey, Jr, MD, MPH, MBA, FACP, FAHA§
Theodore G. Ganiats, MD¶
David R. Holmes, Jr, MD, MACC†
Allan S. Jaffe, MD, FACC, FAHA++)
Hani Jneid, MD, FACC, FAHA, FSCAI†
Rosemary F. Kelly, MD||

Susan J. Zieman, MD, PhD, FACC‡

ACC/AHA TASK FORCE MEMBERS

Jeffrey L. Anderson, MD, FACC, FAHA, Chair
Jonathan L. Halperin, MD, FACC, FAHA, Chair-Elect
Nancy M. Albert, PhD, RN, FAHA
Biykem Bozkurt, MD, PhD, FACC, FAHA
Ralph G. Brindis, MD, MPH, MACC
Lesley H. Curtis, PhD, FAHA
David DeMetts, PhD++
Lee A. Fleisher, MD, FACC, FAHA
Samuel Gidding, MD, FACC++
Robert A. Guyton, MD, FACC++
Clyde W. Yancy, MD, FACC, FAHA++

The writing committee gratefully acknowledges the memory of Dr. Francis M. Fesmire (representative of the American College of Emergency Physicians), who died during the development of this document but contributed immensely to our understanding of non–ST-elevation acute coronary syndromes.

*Writing committee members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply; see Appendix 1 for recusal information. †ACC/AHA Representative. ‡ACC/AHA Task Force on Practice Guidelines Liaison. §American College of Physicians Representative. ¶American Academy of Family Physicians Representative. ||Society of Thoracic Surgeons Representative. #ACC/AHA Task Force on Performance Measures Liaison. **Society for Cardiovascular Angiography and Interventions Representative. ††Former Task Force member; current member during the writing effort.

This document was approved by the American College of Cardiology Board of Trustees and the American Heart Association Science Advisory and Coordinating Committee in August 2014.

The American College of Cardiology requests that this document be cited as follows: Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED,
Amsterdam EA, et al.
2014 AHA/ACC NSTEMI-ACS Executive Summary


This article is copublished in Circulation.

Copies: This document is available on the World Wide Web sites of the American College of Cardiology (www.cardiosource.org) and the American Heart Association (my.americanheart.org). For copies of this document, please contact the Elsevier Inc. Reprint Department, fax (212) 633-3820, e-mail reprints@elsevier.com.

Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American College of Cardiology. Please contact healthpermissions@elsevier.com.

© 2014 by the American Heart Association, Inc., and the American College of Cardiology Foundation.
# Table of Contents

Preamble .................................................................................................................................................................. 5

1. Introduction ............................................................................................................................................................. 8
1.1. Methodology and Evidence Review ................................................................................................................... 8
1.2. Organization of the GWC ........................................................................................................................................ 9
1.3. Document Review and Approval ........................................................................................................................ 9
1.4. Scope of the CPG .................................................................................................................................................. 10

2. Overview of ACS .......................................................................................................................................................... 11

3. Initial Evaluation and Management: Recommendations ............................................................................................ 13
3.1. Clinical Assessment and Initial Evaluation ........................................................................................................ 13
3.2. Emergency Department or Outpatient Facility Presentation .............................................................................. 13
3.3. Prognosis—Early Risk Stratification ................................................................................................................... 13
3.4. Cardiac Biomarkers and the Universal Definition of Myocardial Infarction ....................................................... 17
3.4.1. Biomarkers: Diagnosis .................................................................................................................................. 17
3.4.2. Biomarkers: Prognosis ................................................................................................................................ 17
3.5. Discharge From the ED or Chest Pain Unit .......................................................................................................... 18

4. Early Hospital Care: Recommendations .................................................................................................................... 18
4.1. Standard Medical Therapies ................................................................................................................................ 18
4.1.1. Oxygen .............................................................................................................................................................. 18
4.1.2. Nitrates ............................................................................................................................................................. 18
4.1.3. Analgesic Therapy .......................................................................................................................................... 19
4.1.4. Beta-Adrenergic Blockers ............................................................................................................................... 19
4.1.5. Calcium Channel Blockers ............................................................................................................................ 19
4.1.6. Cholesterol Management ............................................................................................................................... 20
4.2. Inhibitors of Renin-Angiotensin-Aldosterone System .......................................................................................... 21
4.3. Initial Antiplatelet/Anticoagulant Therapy in Patients With Definite or Likely NSTE-ACS ................................. 21

4.3.1. Initial Oral and Intravenous Antiplatelet Therapy in Patients With Definite or Likely NSTE-ACS Treated With
an Initial Invasive or Ischemia-Guided Strategy ........................................................................................................ 21
4.3.2. Initial Parenteral Anticoagulant Therapy in Patients With Definite NSTE-ACS ............................................. 22

4.4. Ischemia-Guided Strategy Versus Early Invasive Strategies .................................................................................. 24
4.4.1. Early Invasive and Ischemia-Guided Strategies ............................................................................................... 26
4.5. Risk Stratification Before Discharge for Patients With an Ischemia-Guided Strategy of NSTE-ACS .................. 27

5. Myocardial Revascularization: Recommendations .................................................................................................. 27
5.1. PCI—General Considerations .............................................................................................................................. 27
5.1.1. PCI—Oral and Intravenous Antiplatelet Agents ............................................................................................... 27
5.1.1.1. PCI—GP IIb/IIIa Inhibitors ........................................................................................................................ 28
5.1.2. Anticoagulant Therapy in Patients Undergoing PCI ...................................................................................... 29

5.2. Timing of Urgent Coronary Artery Bypass Graft in Patients With NSTE-ACS in Relation to Use of Antiplatelet
Agents ..................................................................................................................................................................... 30

6. Late Hospital Care, Hospital Discharge, and Posthospital Discharge Care: Recommendations ..................... 30
6.1. Medical Regimen and Use of Medications at Discharge ..................................................................................... 30
6.2. Late Hospital and Posthospital Oral Antiplatelet Therapy .................................................................................... 31
6.3. Combined Oral Anticoagulant Therapy and Antiplatelet Therapy in Patients With NSTE-ACS .................... 32
6.4. Risk Reduction Strategies for Secondary Prevention .......................................................................................... 32
6.5. Plan of Care for Patients With NSTE-ACS ......................................................................................................... 33

7. Special Patient Groups: Recommendations .............................................................................................................. 33
7.1. NSTE-ACS in Older Patients ............................................................................................................................. 33
7.2. Heart Failure and Cardiogenic Shock .................................................................................................................. 34
7.3. Diabetes Mellitus .................................................................................................................................................. 34
7.4. Post–CABG .......................................................................................................................................................... 34
7.5. Perioperative NSTE-ACS Related to Noncardiac Surgery .................................................................................. 35
7.6. Chronic Kidney Disease .................................................................................................................................. 35
7.7. Women ............................................................................................................................................................... 35
7.8. Anemia, Bleeding, and Transfusion .................................................................................................................... 35
7.9. Cocaine and Methamphetamine Users ............................................................................................................ 36
7.10. Vasospastic (Prinzmetal) Angina ....................................................................................................................... 36
7.11. ACS With Angiographically Normal Coronary Arteries .................................................................................. 36
7.12. Stress (Takotsubo) Cardiomyopathy ................................................................................................................ 37
Amsterdam EA, et al.  
2014 AHA/ACC NSTE-ACS Executive Summary

Preamble

The American College of Cardiology (ACC) and the American Heart Association (AHA) are committed to the prevention and management of cardiovascular diseases through professional education and research for clinicians, providers, and patients. Since 1980, the ACC and AHA have shared a responsibility to translate scientific evidence into clinical practice guidelines (CPGs) with recommendations to standardize and improve cardiovascular health. These CPGs, based on systematic methods to evaluate and classify evidence, provide a cornerstone of quality cardiovascular care.

In response to published reports from the Institute of Medicine (1, 2) and the ACC/AHA’s mandate to evaluate new knowledge and maintain relevance at the point of care, the ACC/AHA Task Force on Practice Guidelines (Task Force) began modifying its methodology. This modernization effort is published in the 2012 Methodology Summit Report (3) and 2014 perspective article (4). The latter recounts the history of the collaboration, changes over time, current policies, and planned initiatives to meet the needs of an evolving healthcare environment. Recommendations on value in proportion to resource utilization will be incorporated as high-quality comparative-effectiveness data become available (5). The relationships between CPGs and data standards, appropriate use criteria, and performance measures are addressed elsewhere (4).

Intended Use—CPGs provide recommendations applicable to patients with or at risk of developing cardiovascular disease. The focus is on medical practice in the United States, but CPGs developed in collaboration with other organizations may have a broader target. Although CPGs may be used to inform regulatory or payer decisions, the intent is to improve the quality of care and be aligned with the patient’s best interest.

Evidence Review—Guideline writing committee (GWC) members are charged with reviewing the literature; weighing the strength and quality of evidence for or against particular tests, treatments, or procedures; and estimating expected health outcomes when data exist. In analyzing the data and developing CPGs, the GWC uses evidence-based methodologies developed by the Task Force (6). A key component of the ACC/AHA CPG methodology is the development of recommendations on the basis of all available evidence. Literature searches focus on randomized controlled trials (RCTs) but also include registries, nonrandomized comparative and descriptive studies, case series, cohort studies, systematic reviews, and expert opinion. Only selected references are cited in the CPG. To ensure that CPGs remain current, new data are reviewed biannually by the GWCs and the Task Force to determine if recommendations should be updated or modified. In general, a target cycle of 5 years is planned for full revisions (1).
Amsterdam EA, et al.
2014 AHA/ACC NSTE-ACS Executive Summary

Guideline-Directed Medical Therapy—Recognizing advances in medical therapy across the spectrum of cardiovascular diseases, the Task Force designated the term “guideline-directed medical therapy” (GDMT) to represent recommended medical therapy as defined mainly by Class I measures, generally a combination of lifestyle modification and drug- and device-based therapeutics. As medical science advances, GDMT evolves, and hence GDMT is preferred to “optimal medical therapy.” For GDMT and all other recommended drug treatment regimens, the reader should confirm the dosage with product insert material and carefully evaluate for contraindications and possible drug interactions. Recommendations are limited to treatments, drugs, and devices approved for clinical use in the United States.

Class of Recommendation and Level of Evidence—Once recommendations are written, the Class of Recommendation (COR; i.e., the strength the GWC assigns to the recommendation, which encompasses the anticipated magnitude and judged certainty of benefit in proportion to risk) is assigned by the GWC. Concurrently, the Level of Evidence (LOE) rates the scientific evidence supporting the effect of the intervention on the basis on the type, quality, quantity, and consistency of data from clinical trials and other reports (Table 1) (4). Unless otherwise stated, recommendations are presented in order by the COR and then the LOE. Where comparative data exist, preferred strategies take precedence. When more than 1 drug, strategy, or therapy exists within the same COR and LOE and there are no comparative data, options are listed alphabetically.

Relationships With Industry and Other Entities—The ACC and AHA exclusively sponsor the work of GWCs without commercial support, and members volunteer their time for this activity. The Task Force makes every effort to avoid actual, potential, or perceived conflicts of interest that might arise through relationships with industry or other entities (RWI). All GWC members and reviewers are required to fully disclose current industry relationships or personal interests from 12 months before initiation of the writing effort. Management of RWI involves selecting a balanced GWC and requires that both the chair and a majority of GWC members have no relevant RWI (see Appendix 1 for the definition of relevance). GWC members are restricted with regard to writing or voting on sections to which their RWI apply. In addition, for transparency, GWC members’ comprehensive disclosure information is available as an online supplement (http://jaccjacc.cardiosource.com/accDocuments/2014_NSTE-ACS_Comprehensive_RWI.pdf). Comprehensive disclosure information for the Task Force is also available at (http://www.cardiosource.org/en/ACC/About-ACC/Who-We-Are/Leadership/Guidelines-and-Documents-Task-Forces.aspx). The Task Force strives to avoid bias by selecting experts from a broad array of backgrounds representing different geographic regions, sexes, ethnicities, races, intellectual perspectives/biases, and scopes of clinical practice. Selected organizations and professional societies with related interests and expertise are invited to participate as partners or collaborators.
Amsterdam EA, et al.
2014 AHA/ACC NSTE-ACS Executive Summary

Individualizing Care in Patients With Associated Conditions and Comorbidities—The ACC and AHA recognize the complexity of managing patients with multiple conditions, compared with managing patients with a single disease, and the challenge is compounded when CPGs for evaluation or treatment of several coexisting illnesses are discordant or interacting (7). CPGs attempt to define practices that meet the needs of patients in most, but not all, circumstances and do not replace clinical judgment.

Clinical Implementation—Management in accordance with CPG recommendations is effective only when followed; therefore, to enhance their commitment to treatment and compliance with lifestyle adjustment, clinicians should engage the patient to participate in selecting interventions on the basis of the patient’s individual values and preferences, taking associated conditions and comorbidities into consideration (e.g., shared decision making). Consequently, there are circumstances in which deviations from these guidelines are appropriate.

The recommendations in this CPG are the official policy of the ACC and AHA until they are superseded by a published addendum, focused update, or revised full-text CPG. The reader is encouraged to consult the full-text CPG (8) for additional guidance and details about the management of patients with non–ST-elevation acute coronary syndrome (NSTE-ACS) because the executive summary contains mainly the recommendations.

Jeffrey L. Anderson, MD, FACC, FAHA
Chair, ACC/AHA Task Force on Practice Guidelines
A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the clinical practice guidelines do not lend themselves to clinical trials. Although randomized trials are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.

*Data available from clinical trials or registries about the usefulness/efficacy in different subpopulations, such as sex, age, history of diabetes mellitus, history of prior myocardial infarction, history of heart failure, and prior aspirin use.
†For comparative-effectiveness recommendations (Class I and IIa; Level of Evidence A and B only), studies that support the use of comparator verbs should involve direct comparisons of the treatments or strategies being evaluated

1. Introduction

1.1. Methodology and Evidence Review

The recommendations listed in this CPG are, whenever possible, evidence based. An extensive evidence review was conducted through October 2012, and other selected references published through April 2014 were reviewed by the GWC. Literature included was derived from research involving human subjects, published in
Amsterdam EA, et al.
2014 AHA/ACC NSTE-ACS Executive Summary

English, and indexed in MEDLINE (through PubMed), EMBASE, the Cochrane Library, Agency for Healthcare Research and Quality Reports, and other selected databases relevant to this CPG. The relevant data are included in evidence tables in the Data Supplement available online at (http://jaccjacc.cardiosource.com/acc_documents/2014_NSTE-ACS_Data_Supplement_Tables.pdf). Key search words included but were not limited to the following: acute coronary syndrome, anticoagulant therapy, antihypertensives, anti-ischemic therapy, antiplatelet therapy, antithrombotic therapy, beta blockers, biomarkers, calcium channel blockers, cardiac rehabilitation, conservative management, diabetes mellitus, glycoprotein IIb/IIIa inhibitors, heart failure, invasive strategy, lifestyle modification, myocardial infarction, nitrates, non-ST elevation, P2Y12 receptor inhibitor, percutaneous coronary intervention, renin-angiotensin-aldosterone inhibitors, secondary prevention, smoking cessation, statins, stent, thienopyridines, troponins, unstable angina, and weight management. Additionally, the GWC reviewed documents related to NSTE-ACS previously published by the ACC and AHA. References selected and published in this document are representative and not all-inclusive.

1.2. Organization of the GWC

The GWC was composed of clinicians, cardiologists, internists, interventionists, surgeons, emergency medicine specialists, family practitioners, and geriatricians. The GWC included representatives from the ACC and AHA, American Academy of Family Physicians, American College of Emergency Physicians, American College of Physicians, Society for Cardiovascular Angiography and Interventions (SCAI), and Society of Thoracic Surgeons.

1.3. Document Review and Approval

This document was reviewed by 2 official reviewers each nominated by the ACC and AHA; 1 reviewer each from the American Academy of Family Physicians, American College of Emergency Physicians, SCAI, and STS; and 37 individual content reviewers (including members of the American Association of Clinical Chemistry, ACC Heart Failure and Transplant Section Leadership Council, ACC Cardiovascular Imaging Section Leadership Council, ACC Interventional Section Leadership Council, ACC Prevention of Cardiovascular Disease Committee, ACC Surgeons’ Council, Association of International Governors, and Department of Health and Human Services). Reviewers’ RWI information was distributed to the GWC and is published in this document (Appendix 2).

This document was approved for publication by the governing bodies of the ACC and the AHA and endorsed by the American Association for Clinical Chemistry and the Society of Thoracic Surgeons.

1.4. Scope of the CPG

The 2014 NSTE-ACS CPG is a full revision of the 2007 ACCF/AHA CPG for the management of patients with unstable angina (UA) and non–ST-elevation myocardial infarction (NSTEMI) and the 2012 focused update (9).
Amsterdam EA, et al.  
2014 AHA/ACC NSTE-ACS Executive Summary

The new title, “Non–ST-Elevation Acute Coronary Syndromes,” emphasizes the continuum between UA and NSTEMI. At presentation, patients with UA and NSTEMI can be indistinguishable and are therefore considered together in this CPG.

In the United States, NSTE-ACS affects >625,000 patients annually, or almost three fourths of all patients with acute coronary syndrome (ACS) (10). In selecting the initial approach to care, the term “ischemia-guided strategy” has replaced the previous descriptor, “initial conservative management,” to more clearly convey the physiological rationale of this approach.

The task of the 2014 GWC was to establish a contemporary CPG for the optimal management of patients with NSTE-ACS. It incorporates both established and new evidence from published clinical trials, as well as information from basic science and comprehensive review articles. These recommendations were developed to guide the clinician in improving outcomes for patients with NSTE-ACS. Table 2 lists documents deemed pertinent to this effort and is intended for use as a resource, thus obviating the need to repeat extant CPG recommendations.

The GWC abbreviated the discussion sections to include an explanation of salient information related to the recommendations. In contrast to textbook declaratory presentations, explanations were supplemented with evidence tables. The GWC also provided a brief summary of the relevant recommendations and references related to secondary prevention rather than detailed reiteration. Throughout, the goal was to provide the clinician with concise, evidence-based contemporary recommendations and the supporting documentation to encourage their application.

Table 2. Associated CPGs and Statements

<table>
<thead>
<tr>
<th>Title</th>
<th>Organization</th>
<th>Publication Year (Reference)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stable ischemic heart disease</td>
<td>ACC/AHA/AATS/PCNA/SCAI/STS</td>
<td>2014 (11)*</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>AHA/ACC/HRS</td>
<td>2014 (13)</td>
</tr>
<tr>
<td>Assessment of cardiovascular risk</td>
<td>ACC/AHA</td>
<td>2013 (14)</td>
</tr>
<tr>
<td>Heart failure</td>
<td>ACC/AHA</td>
<td>2013 (15)</td>
</tr>
<tr>
<td>Lifestyle management to reduce cardiovascular risk</td>
<td>AHA/ACC</td>
<td>2013 (16)</td>
</tr>
<tr>
<td>Management of overweight and obesity in adults</td>
<td>AHA/ACC/TOS</td>
<td>2013 (17)</td>
</tr>
<tr>
<td>ST-elevation myocardial infarction</td>
<td>ACC/AHA</td>
<td>2013 (18)</td>
</tr>
<tr>
<td>Treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults</td>
<td>ACC/AHA</td>
<td>2013 (19)</td>
</tr>
<tr>
<td>Acute myocardial infarction in patients presenting with ST-segment elevation</td>
<td>ESC</td>
<td>2012 (20)</td>
</tr>
<tr>
<td>Device-based therapy</td>
<td>ACC/AHA/HRS</td>
<td>2013 (21)</td>
</tr>
<tr>
<td>Third universal definition of myocardial infarction</td>
<td>ESC/ACC/AHA/WHF</td>
<td>2012 (22)</td>
</tr>
<tr>
<td>Acute coronary syndromes in patients presenting without persistent ST-segment elevation</td>
<td>ESC</td>
<td>2011 (23)</td>
</tr>
<tr>
<td>Coronary artery bypass graft surgery</td>
<td>ACC/AHA</td>
<td>2011 (24)</td>
</tr>
<tr>
<td>Hypertrophic cardiomyopathy</td>
<td>ACC/AHA</td>
<td>2011 (25)</td>
</tr>
</tbody>
</table>

*Estimate includes secondary discharge diagnoses.
2. Overview of ACS

ACS has evolved as a useful operational term that refers to a spectrum of conditions compatible with acute myocardial ischemia and/or infarction due to an abrupt reduction in coronary blood flow (Figure 1).
Figure 1. Acute Coronary Syndromes

The top half of the figure illustrates the progression of plaque formation and onset and complications of NSTE-ACS, with management at each stage. The numbered section of an artery depicts the process of atherogenesis from 1) normal artery to 2) extracellular lipid in the subintima to 3) fibrofatty stage to 4) procoagulant expression and weakening of the fibrous cap. ACS develops with 5) disruption of the fibrous cap, which is the stimulus for thrombogenesis. 6) Thrombus resorption may be followed by collagen accumulation and smooth muscle cell growth. Thrombus formation and possible coronary vasospasm reduce blood flow in the affected coronary artery and cause ischemic chest pain.

The bottom half of the figure illustrates the clinical, pathological, electrocardiographic, and biomarker correlates in ACS and the general approach to management. Flow reduction may be related to a completely occlusive thrombus (bottom half, right side) or subtotally occlusive thrombus (bottom half, left side). Most patients with ST elevation (thick white arrow in bottom panel) develop QwMI, and a few (thin white arrow) develop NQMI. Those without ST elevation have either UA or NSTEMI (thick red arrows), a distinction based on cardiac biomarkers. Most patients presenting with NSTEMI develop NQMI; a few may develop QwMI. The spectrum of clinical presentations including UA, NSTEMI, and STEMI is referred
Amsterdam EA, et al.
2014 AHA/ACC NSTE-ACS Executive Summary

to as ACS. This NSTE-ACS CPG includes sections on initial management before NSTE-ACS, at the onset of NSTE-ACS, and during the hospital phase. Secondary prevention and plans for long-term management begin early during the hospital phase. Patients with noncardiac etiologies make up the largest group presenting to the ED with chest pain (dashed arrow).

*Elevated cardiac biomarker (e.g., troponin), Section 3.4.

ACS indicates acute coronary syndrome; CPG, clinical practice guideline; Dx, diagnosis; ECG, electrocardiogram; ED, emergency department; MI, myocardial infarction; NQMI, non–Q-wave myocardial infarction; NSTE-ACS, non–ST-elevation acute coronary syndromes; NSTEMI, non–ST-elevation myocardial infarction; QwMI, Q-wave myocardial infarction; STEMI, ST-elevation myocardial infarction; and UA, unstable angina.

Modified with permission from Libby et al (39).

3. Initial Evaluation and Management: Recommendations

3.1. Clinical Assessment and Initial Evaluation

Class I
1. Patients with suspected ACS should be risk stratified based on the likelihood of ACS and adverse outcome(s) to decide on the need for hospitalization and assist in the selection of treatment options (40-42). *(Level of Evidence: B)*

3.2. Emergency Department or Outpatient Facility Presentation

Class I
1. Patients with suspected ACS and high-risk features such as continuing chest pain, severe dyspnea, syncope/presyncope, or palpitations should be referred immediately to the emergency department (ED) and transported by emergency medical services when available. *(Level of Evidence: C)*

Class IIb
1. Patients with less severe symptoms may be considered for referral to the ED, a chest pain unit, or a facility capable of performing adequate evaluation depending on clinical circumstances. *(Level of Evidence: C)*

3.3. Prognosis—Early Risk Stratification

See Table 4 for a summary of recommendations from this section.

Class I
1. In patients with chest pain or other symptoms suggestive of ACS, a 12-lead electrocardiogram (ECG) should be performed and evaluated for ischemic changes within 10 minutes of the patient’s arrival at an emergency facility (22). *(Level of Evidence: C)*

2. If the initial ECG is not diagnostic but the patient remains symptomatic and there is a high clinical suspicion for ACS, serial ECGs (e.g., 15- to 30-minute intervals during the first hour) should be performed to detect ischemic changes. *(Level of Evidence: C)*

3. Serial cardiac troponin I or T levels (when a contemporary assay is used) should be obtained at presentation and 3 to 6 hours after symptom onset (see Section 3.4.1, Class I, #3 recommendation if time of symptom onset is unclear) in all patients who present with symptoms consistent with ACS to identify a rising and/or falling pattern of values (22, 43-48). *(Level of Evidence: A)*

4. Additional troponin levels should be obtained beyond 6 hours after symptom onset (see Section 3.4.1, Class I, #3 recommendation if time of symptom onset is unclear) in patients with normal
Amsterdam EA, et al.
2014 AHA/ACC NSTE-ACS Executive Summary

troponin levels on serial examination when changes on ECG and/or clinical presentation confer an intermediate or high index of suspicion for ACS (22, 49-51). *(Level of Evidence: A)*

5. Risk scores should be used to assess prognosis in patients with NSTE-ACS (40-42, 52-57). *(Level of Evidence: A)*

Class IIa

1. Risk-stratification models can be useful in management (40-42, 52-58). *(Level of Evidence: B)*

2. It is reasonable to obtain supplemental electrocardiographic leads V7 to V9 in patients whose initial ECG is nondiagnostic and who are at intermediate/high risk of ACS (59-61). *(Level of Evidence: B)*

Class IIb

1. Continuous monitoring with 12-lead ECG may be a reasonable alternative in patients whose initial ECG is nondiagnostic and who are at intermediate/high risk of ACS (62, 63). *(Level of Evidence: B)*

2. Measurement of B-type natriuretic peptide or N-terminal pro–B-type natriuretic peptide may be considered to assess risk in patients with suspected ACS (64-68). *(Level of Evidence: B)*

Table 3. TIMI Risk Score* for NSTE-ACS

<table>
<thead>
<tr>
<th>TIMI Risk Score</th>
<th>All-Cause Mortality, New or Recurrent MI, or Severe Recurrent Ischemia Requiring Urgent Revascularization Through 14 d After Randomization, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>0–1</td>
<td>4.7</td>
</tr>
<tr>
<td>2</td>
<td>8.3</td>
</tr>
<tr>
<td>3</td>
<td>13.2</td>
</tr>
<tr>
<td>4</td>
<td>19.9</td>
</tr>
<tr>
<td>5</td>
<td>26.2</td>
</tr>
<tr>
<td>6–7</td>
<td>40.9</td>
</tr>
</tbody>
</table>

*The TIMI risk score is determined by the sum of the presence of 7 variables at admission; 1 point is given for each of the following variables: ≥65 y of age; ≥3 risk factors for CAD; prior coronary stenosis ≥50%; ST deviation on ECG; ≥2 anginal events in prior 24 h; use of aspirin in prior 7 d; and elevated cardiac biomarkers.

CAD indicates coronary artery disease; ECG, electrocardiogram; MI, myocardial infarction; NSTE-ACS, non–ST-elevation acute coronary syndromes; and TIMI, Thrombolysis In Myocardial Infarction. Modified with permission from Antman et al. (40).
Figure 2. Global Registry of Acute Coronary Events Risk Calculator for In-Hospital Mortality for Acute Coronary Syndrome

A. GRACE Risk Model Nomogram

1. Find Points for Each Predictive Factor:

<table>
<thead>
<tr>
<th>Killip Class</th>
<th>Points</th>
<th>SBP (mm Hg)</th>
<th>Points</th>
<th>Heart Rate (beats/min)</th>
<th>Points</th>
<th>Age, y</th>
<th>Points</th>
<th>Creatinine Level, mg/dL</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>0</td>
<td>≤90</td>
<td>80</td>
<td>≤90</td>
<td>0</td>
<td>≤60</td>
<td>0</td>
<td>≤0.39</td>
<td>1</td>
</tr>
<tr>
<td>II</td>
<td>20</td>
<td>90-109</td>
<td>53</td>
<td>100-119</td>
<td>43</td>
<td>109-109</td>
<td>9</td>
<td>10-29</td>
<td>8</td>
</tr>
<tr>
<td>III</td>
<td>59</td>
<td>120-139</td>
<td>24</td>
<td>130-149</td>
<td>12</td>
<td>140-169</td>
<td>24</td>
<td>120-199</td>
<td>38</td>
</tr>
<tr>
<td>IV</td>
<td>160-189</td>
<td>≤200</td>
<td>0</td>
<td>≤200</td>
<td>48</td>
<td>≤200</td>
<td>0</td>
<td>≥0.5</td>
<td>28</td>
</tr>
</tbody>
</table>

2. Sum Points for All Predictive Factors

3. Look-Up Risk Corresponding to Total Points:

To convert serum creatine level to micromoles per liter, multiply by 88.4.

SBP indicates systolic blood pressure.

Reprinted with permission from Granger et al. (69).
Amsterdam EA, et al.
2014 AHA/ACC NSTE-ACS Executive Summary

B. Calibration of Simplified Global Registry of ACS Mortality Model

ACS indicates acute coronary syndrome.
Reprinted with permission from Granger et al. (69).

Table 4. Summary of Recommendations for Prognosis: Early Risk Stratification

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>COR</th>
<th>LOE</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Perform rapid determination of likelihood of ACS, including a 12-lead ECG within 10 min of arrival at an emergency facility, in patients whose symptoms suggest ACS</td>
<td>I</td>
<td>C</td>
<td>(22)</td>
</tr>
<tr>
<td>Perform serial ECGs at 15- to 30-min intervals during the first hour in symptomatic patients with initial nondiagnostic ECG</td>
<td>I</td>
<td>C</td>
<td>N/A</td>
</tr>
<tr>
<td>Measure cardiac troponin (cTnI or cTnT) in all patients with symptoms consistent with ACS*</td>
<td>I</td>
<td>A</td>
<td>(22, 43-48)</td>
</tr>
<tr>
<td>Measure serial cardiac troponin I or T at presentation and 3–6 h after symptom onset* in all patients with symptoms consistent with ACS</td>
<td>I</td>
<td>A</td>
<td>(22, 49-51)</td>
</tr>
<tr>
<td>Use risk scores to assess prognosis in patients with NSTE-ACS</td>
<td>I</td>
<td>A</td>
<td>(40-42, 52-57)</td>
</tr>
<tr>
<td>Risk-stratification models can be useful in management</td>
<td>IIa</td>
<td>B</td>
<td>(40-42, 52-58)</td>
</tr>
<tr>
<td>Obtain supplemental electrocardiographic leads V(_7) to V(_9) in patients with initial nondiagnostic ECG at intermediate/high risk for ACS</td>
<td>IIa</td>
<td>B</td>
<td>(59-61)</td>
</tr>
<tr>
<td>Continuous monitoring with 12-lead ECG may be a reasonable alternative with initial nondiagnostic ECG in patients at intermediate/high risk for ACS</td>
<td>IIb</td>
<td>B</td>
<td>(62, 63)</td>
</tr>
<tr>
<td>BNP or NT–pro-BNP may be considered to assess risk in patients with suspected ACS</td>
<td>IIb</td>
<td>B</td>
<td>(64-68)</td>
</tr>
</tbody>
</table>

*See Section 3.4.1, Class I, #3 recommendation if time of symptom onset is unclear.

ACS indicates acute coronary syndromes; BNP, B-type natriuretic peptide; COR, Class of Recommendation; cTnI, cardiac troponin I; cTnT, cardiac troponin T; ECG, electrocardiogram; LOE, Level of Evidence; N/A, not available; NSTE-ACS, non–ST-elevation acute coronary syndromes; and NT–pro-BNP, N-terminal pro–B-type natriuretic peptide.
3.4. Cardiac Biomarkers and the Universal Definition of Myocardial Infarction

See Table 5 for a summary of recommendations from this section.

3.4.1. Biomarkers: Diagnosis

Class I

1. Cardiac-specific troponin (troponin I or T when a contemporary assay is used) levels should be measured at presentation and 3 to 6 hours after symptom onset in all patients who present with symptoms consistent with ACS to identify a rising and/or falling pattern (22, 43-48, 70-74). *(Level of Evidence: A)*

2. Additional troponin levels should be obtained beyond 6 hours after symptom onset in patients with normal troponins on serial examination when electrocardiographic changes and/or clinical presentation confer an intermediate or high index of suspicion for ACS (22, 49-51, 75). *(Level of Evidence: A)*

3. If the time of symptom onset is ambiguous, the time of presentation should be considered the time of onset for assessing troponin values (44, 45, 49). *(Level of Evidence: A)*

Class III: No Benefit

1. With contemporary troponin assays, creatine kinase myocardial isoenzyme (CK-MB) and myoglobin are not useful for diagnosis of ACS (76-82). *(Level of Evidence: A)*

3.4.2. Biomarkers: Prognosis

Class I

1. The presence and magnitude of troponin elevations are useful for short- and long-term prognosis (48, 50, 83, 84). *(Level of Evidence: B)*

Class IIb

1. It may be reasonable to remeasure troponin once on day 3 or day 4 in patients with a myocardial infarction (MI) as an index of infarct size and dynamics of necrosis (82, 83). *(Level of Evidence: B)*

2. Use of selected newer biomarkers, especially B-type natriuretic peptide, may be reasonable to provide additional prognostic information (64, 65, 85-89). *(Level of Evidence: B)*

Table 5. Summary of Recommendations for Cardiac Biomarkers and the Universal Definition of MI

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>COR</th>
<th>LOE</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Diagnosis</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measure cardiac-specific troponin (troponin I or T) at presentation and 3–6 h after symptom onset in all patients with suspected ACS to identify pattern of values</td>
<td>I</td>
<td>A</td>
<td>(22, 43-48, 70-74)</td>
</tr>
<tr>
<td>Obtain additional troponin levels beyond 6 h in patients with initial normal serial troponins with electrocardiographic changes and/or intermediate/high risk clinical features</td>
<td>I</td>
<td>A</td>
<td>(22, 49-51, 75)</td>
</tr>
<tr>
<td>Consider time of presentation the time of onset with ambiguous symptom onset for assessing troponin values</td>
<td>I</td>
<td>A</td>
<td>(44, 45, 49)</td>
</tr>
<tr>
<td>With contemporary troponin assays, CK-MB and myoglobin are not useful for diagnosis of ACS</td>
<td>III: No Benefit</td>
<td>A</td>
<td>(76-82)</td>
</tr>
<tr>
<td><strong>Prognosis</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Troponin elevations are useful for short- and long-term prognosis</td>
<td>I</td>
<td>B</td>
<td>(48, 50, 83, 84)</td>
</tr>
<tr>
<td>Remeasurement of troponin value once on d 3 or 4 in patients with MI may be reasonable as an index of infarct size and dynamics of necrosis</td>
<td>IIb</td>
<td>B</td>
<td>(82, 83)</td>
</tr>
<tr>
<td>BNP may be reasonable for additional prognostic information</td>
<td>IIb</td>
<td>B</td>
<td>(64, 65, 85-89)</td>
</tr>
</tbody>
</table>
ACS indicates acute coronary syndromes; BNP, B-type natriuretic peptide; CK-MB, creatine kinase myocardial isoenzyme; COR, Class of Recommendation; LOE, Level of Evidence; and MI, myocardial infarction.

3.5. Discharge From the ED or Chest Pain Unit

Class IIa
1. It is reasonable to observe patients with symptoms consistent with ACS without objective evidence of myocardial ischemia (nonischemic initial ECG and normal cardiac troponin) in a chest pain unit or telemetry unit with serial ECGs and cardiac troponin at 3- to 6-hour intervals (90-94). (Level of Evidence: B)
2. It is reasonable for patients with possible ACS who have normal serial ECGs and cardiac troponins to have a treadmill ECG (93-95), stress myocardial perfusion imaging (93), or stress echocardiography (96, 97) before discharge or within 72 hours after discharge. (Level of Evidence: B)
3. In patients with possible ACS and a normal ECG, normal cardiac troponins, and no history of coronary artery disease (CAD), it is reasonable to initially perform (without serial ECGs and troponins) coronary computed tomography angiography to assess coronary artery anatomy (98-100) (Level of Evidence: A) or rest myocardial perfusion imaging with a technetium-99m radiopharmaceutical to exclude myocardial ischemia (101, 102). (Level of Evidence: B)
4. It is reasonable to give low-risk patients who are referred for outpatient testing daily aspirin, short-acting nitroglycerin, and other medication if appropriate (e.g., beta blockers), with instructions about activity level and clinician follow-up. (Level of Evidence: C)

4. Early Hospital Care: Recommendations

See Table 6 for a summary of recommendations from this section.

4.1. Standard Medical Therapies

4.1.1. Oxygen

Class I
1. Supplemental oxygen should be administered to patients with NSTE-ACS with arterial oxygen saturation less than 90%, respiratory distress, or other high-risk features of hypoxemia. (Level of Evidence: C)

4.1.2. Nitrates

Class I
1. Patients with NSTE-ACS with continuing ischemic pain should receive sublingual nitroglycerin (0.3 mg–0.4 mg) every 5 minutes for up to 3 doses, after which an assessment should be made about the need for intravenous nitroglycerin if not contraindicated (103-105). (Level of Evidence: C)
2. Intravenous nitroglycerin is indicated for patients with NSTE-ACS for the treatment of persistent ischemia, heart failure (HF), or hypertension (106-111). (Level of Evidence: B)

Class III: Harm
1. Nitrates should not be administered to patients with NSTE-ACS who recently received a phosphodiesterase inhibitor, especially within 24 hours of sildenafil or vardenafil, or within 48 hours of tadalafil (112-114). (Level of Evidence: B)
4.1.3. Analgesic Therapy

Class IIb
1. In the absence of contraindications, it may be reasonable to administer morphine sulfate intravenously to patients with NSTE-ACS if there is continued ischemic chest pain despite treatment with maximally tolerated anti-ischemic medications (115, 116). (Level of Evidence: B)

Class III: Harm
1. Nonsteroidal anti-inflammatory drugs (NSAIDs) (except aspirin) should not be initiated and should be discontinued during hospitalization for NSTE-ACS because of the increased risk of MACE associated with their use (117, 118). (Level of Evidence: B)

4.1.4. Beta-Adrenergic Blockers

Class I
1. Oral beta-blocker therapy should be initiated within the first 24 hours in patients who do not have any of the following: 1) signs of HF, 2) evidence of low-output state, 3) increased risk for cardiogenic shock, or 4) other contraindications to beta blockade (e.g., PR interval >0.24 second, second- or third-degree heart block without a cardiac pacemaker, active asthma, or reactive airway disease) (119-121). (Level of Evidence: A)
2. In patients with concomitant NSTE-ACS, stabilized HF, and reduced systolic function, it is recommended to continue beta-blocker therapy with 1 of the 3 drugs proven to reduce mortality in patients with HF: sustained-release metoprolol succinate, carvedilol, or bisoprolol. (Level of Evidence: C)
3. Patients with documented contraindications to beta blockers in the first 24 hours of NSTE-ACS should be reevaluated to determine their subsequent eligibility. (Level of Evidence: C)

Class IIa
1. It is reasonable to continue beta-blocker therapy in patients with normal left ventricular (LV) function with NSTE-ACS (120, 122). (Level of Evidence: C)

Class III: Harm
1. Administration of intravenous beta blockers is potentially harmful in patients with NSTE-ACS who have risk factors for shock (123). (Level of Evidence: B)

4.1.5. Calcium Channel Blockers

Class I
1. In patients with NSTE-ACS, continuing or frequently recurring ischemia, and a contraindication to beta blockers, a nondihydropyridine calcium channel blocker (CCB) (e.g., verapamil or diltiazem) should be given as initial therapy in the absence of clinically significant LV dysfunction, increased risk for cardiogenic shock, PR interval greater than 0.24 second, or second- or third-degree atrioventricular block without a cardiac pacemaker (124-126). (Level of Evidence: B)
2. Oral nondihydropyridine calcium antagonists are recommended in patients with NSTE-ACS who have recurrent ischemia in the absence of contraindications, after appropriate use of beta blockers and nitrates. (Level of Evidence: C)
3. CCBs are recommended for ischemic symptoms when beta blockers are not successful, are contraindicated, or cause unacceptable side effects. (Level of Evidence: C)
4. Long-acting CCBs and nitrates are recommended in patients with coronary artery spasm. (Level of Evidence: C)

† Short-acting dihydropyridine calcium channel antagonists should be avoided.
Amsterdam EA, et al. 2014 AHA/ACC NSTE-ACS Executive Summary

Class III: Harm
1. Immediate-release nifedipine should not be administered to patients with NSTE-ACS in the absence of beta-blocker therapy (127, 128). (Level of Evidence: B)

4.1.6. Cholesterol Management

Class I
1. High-intensity statin therapy should be initiated or continued in all patients with NSTE-ACS and no contraindications to its use (129-133). (Level of Evidence: A)

Class IIa
1. It is reasonable to obtain a fasting lipid profile in patients with NSTE-ACS, preferably within 24 hours of presentation. (Level of Evidence: C)

Table 6. Summary of Recommendations for Early Hospital Care

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>COR</th>
<th>LOE</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxygen</td>
<td>I</td>
<td>C</td>
<td>N/A</td>
</tr>
<tr>
<td>Administer supplemental oxygen only with oxygen saturation &lt;90%, respiratory distress, or other high-risk features for hypoxemia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nitrates</td>
<td>I</td>
<td>C</td>
<td>(103-105)</td>
</tr>
<tr>
<td>Administer sublingual NTG every 5 min × 3 for continuing ischemic pain and then assess need for IV NTG</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Administer IV NTG for persistent ischemia, HF, or hypertension</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nitrates are contraindicated with recent use of a phosphodiesterase inhibitor</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Analgesic therapy</td>
<td>IIb</td>
<td>B</td>
<td>(115, 116)</td>
</tr>
<tr>
<td>IV morphine sulfate may be reasonable for continued ischemic chest pain despite maximally tolerated anti-ischemic medications</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NSAIADs (except aspirin) should not be initiated and should be discontinued during hospitalization for NSTE-ACS because of the increased risk of MACE associated with their use</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beta-adrenergic blockers</td>
<td>I</td>
<td>A</td>
<td>(119-121)</td>
</tr>
<tr>
<td>Initiate oral beta blockers within the first 24 h in the absence of HF, low-output state, risk for cardiogenic shock, or other contraindications to beta blockade</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Use of sustained-release metoprolol succinate, carvedilol, or bisoprolol is recommended for beta-blocker therapy with concomitant NSTE-ACS, stabilized HF, and reduced systolic function</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Re-evaluate to determine subsequent eligibility in patients with initial contraindications to beta blockers</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>It is reasonable to continue beta-blocker therapy in patients with normal LV function</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IV beta blockers are potentially harmful when risk factors for shock are present</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CCBs</td>
<td>I</td>
<td>B</td>
<td>(124-126)</td>
</tr>
<tr>
<td>Administer initial therapy with nondihydropyridine CCBs with recurrent ischemia and contraindications to beta blockers in the absence of LV dysfunction, increased risk for cardiogenic shock, PR interval &gt;0.24 s, or second- or third-degree atrioventricular block without a cardiac pacemaker</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Administer oral nondihydropyridine calcium antagonists with recurrent ischemia after use of beta blocker and nitrates in the absence of contraindications</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CCBs are recommended for ischemic symptoms when beta blockers are not successful, are contraindicated, or cause unacceptable side effects*</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Long-acting CCBs and nitrates are recommended for patients with coronary
artery spasm

Immediate-release nifedipine is contraindicated in the absence of a beta blocker

III: Harm B (127, 128)

Cholesterol management

Initiate or continue high-intensity statin therapy in patients with no contraindications

I A (129-133)

Obtain a fasting lipid profile, preferably within 24 h

IIa C N/A (129-133)

*Short-acting dihydropyridine calcium channel antagonists should be avoided.

CCB indicates calcium channel blocker; COR, Class of Recommendation; HF, heart failure; IV, intravenous; LOE, Level of Evidence; LV, left ventricular; MACE, major adverse cardiac event; N/A, not available; NSAIDs, nonsteroidal anti-inflammatory drugs; NSTE-ACS, non-ST-elevation acute coronary syndromes; and NTG, nitroglycerin.

4.2. Inhibitors of Renin-Angiotensin-Aldosterone System

Class I

1. Angiotensin-converting enzyme (ACE) inhibitors should be started and continued indefinitely in all patients with left ventricular ejection fraction (LVEF) less than 0.40 and in those with hypertension, diabetes mellitus, or stable chronic kidney disease (CKD) (Section 7.6), unless contraindicated (134, 135). (Level of Evidence: A)

2. Angiotensin receptor blockers are recommended in patients with HF or MI with LVEF less than 0.40 who are ACE inhibitor intolerant (136, 137). (Level of Evidence: A)

3. Aldosterone blockade is recommended in post–MI patients who are without significant renal dysfunction (creatinine >2.5 mg/dL in men or >2.0 mg/dL in women) or hyperkalemia (K >5.0 mEq/L) who are receiving therapeutic doses of ACE inhibitor and beta blocker and have a LVEF 0.40 or less, diabetes mellitus, or HF (138). (Level of Evidence: A)

Class IIa

1. Angiotensin receptor blockers are reasonable in other patients with cardiac or other vascular disease who are ACE inhibitor intolerant (139). (Level of Evidence: B)

Class IIb

1. ACE inhibitors may be reasonable in all other patients with cardiac or other vascular disease (140, 141). (Level of Evidence: B)

4.3. Initial Antiplatelet/Anticoagulant Therapy in Patients With Definite or Likely NSTE-ACS

4.3.1. Initial Oral and Intravenous Antiplatelet Therapy in Patients With Definite or Likely NSTE-ACS Treated With an Initial Invasive or Ischemia-Guided Strategy

See Table 7 for a summary of recommendations from this section.

Class I

1. Non-enteric-coated, chewable aspirin (162 mg to 325 mg) should be given to all patients with NSTE-ACS without contraindications as soon as possible after presentation, and a maintenance dose of aspirin (81 mg/d to 162 mg/d) should be continued indefinitely (142-144). (Level of Evidence: A)

2. In patients with NSTE-ACS who are unable to take aspirin because of hypersensitivity or major gastrointestinal intolerance, a loading dose of clopidogrel followed by a daily maintenance dose should be administered (145). (Level of Evidence: B)

1See Section 5.1 for recommendations at the time of PCI.
3. A P2Y₁₂ inhibitor (either clopidogrel or ticagrelor) in addition to aspirin should be administered for up to 12 months to all patients with NSTE-ACS without contraindications who are treated with either an early invasive or ischemia-guided strategy. Options include:
   - Clopidogrel: 300-mg or 600-mg loading dose, then 75 mg daily (143, 146) (Level of Evidence: B)
   - Ticagrelor: 180-mg loading dose, then 90 mg twice daily (147, 148) (Level of Evidence: B)

Class IIa
1. It is reasonable to use ticagrelor in preference to clopidogrel for P2Y₁₂ treatment in patients with NSTE-ACS who undergo an early invasive or ischemia-guided strategy (147, 148). (Level of Evidence: B)

Class IIb
1. In patients with NSTE-ACS treated with an early invasive strategy and dual antiplatelet therapy (DAPT) with intermediate/high-risk features (e.g., positive troponin), a glycoprotein (GP) IIb/IIIa inhibitor may be considered as part of initial antiplatelet therapy. Preferred options are eptifibatide or tirofiban (41, 149, 150). (Level of Evidence: B)

4.3.2. Initial Parenteral Anticoagulant Therapy in Patients With Definite NSTE-ACS
See Table 7 for a summary of recommendations from this section.

Class I
1. In patients with NSTE-ACS, anticoagulation, in addition to antiplatelet therapy, is recommended for all patients irrespective of initial treatment strategy. Treatment options include:
   - Enoxaparin: 1 mg/kg subcutaneous (SC) every 12 hours (reduce dose to 1 mg/kg SC once daily in patients with creatinine clearance [CrCl] <30 mL/min), continued for the duration of hospitalization or until percutaneous coronary intervention (PCI) is performed. An initial intravenous loading dose is 30 mg (151-153). (Level of Evidence: A)
   - Bivalirudin: 0.10 mg/kg loading dose followed by 0.25 mg/kg per hour (only in patients managed with an early invasive strategy), continued until diagnostic angiography or PCI, with only provisional use of GP IIb/IIIa inhibitor, provided the patient is also treated with DAPT (146, 147, 154, 155). (Level of Evidence: B)
   - Fondaparinux: 2.5 mg SC daily, continued for the duration of hospitalization or until PCI is performed (156-158). (Level of Evidence: B)
   - If PCI is performed while the patient is on fondaparinux, an additional anticoagulant with anti-IIa activity (either UFH or bivalirudin) should be administered because of the risk of catheter thrombosis (157-159). (Level of Evidence: B)
   - UFH IV: initial loading dose of 60 IU/kg (maximum 4,000 IU) with initial infusion of 12 IU/kg per hour (maximum 1,000 IU/h) adjusted per activated partial thromboplastin time to maintain therapeutic anticoagulation according to the specific hospital protocol, continued for 48 hours or until PCI is performed (160-166). (Level of Evidence: B)

Class III: Harm
1. In patients with NSTE-ACS (i.e., without ST elevation, true posterior MI, or left bundle-branch block not known to be old), intravenous fibrinolytic therapy should not be used (167, 168). (Level of Evidence: A)

---

1See Section 4.3.1.2 in the full-text CPG for prasugrel indications in either an early invasive or ischemia-guided strategy.
2The recommended maintenance dose of aspirin to be used with ticagrelor is 81 mg daily (144).
3See Section 5.1 for recommendations at the time of PCI.
Table 7. Summary of Recommendations for Initial Antiplatelet/Anticoagulant Therapy in Patients With Definite or Likely NSTE-ACS and PCI

See Section 5.1 for recommendations on antiplatelet/anticoagulant therapy at the time of PCI and Sections 6.2 and 6.3 for recommendations on posthospital therapy.

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Dosing and Special Considerations</th>
<th>COR</th>
<th>LOE</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Aspirin</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Non-enteric-coated aspirin to all patients promptly after presentation</td>
<td>162 mg–325 mg</td>
<td>I</td>
<td>A</td>
<td>(142-144)</td>
</tr>
<tr>
<td>• Aspirin maintenance dose continued indefinitely</td>
<td>81 mg/d–162 mg/d</td>
<td>I</td>
<td>A</td>
<td>(142-144)</td>
</tr>
<tr>
<td><strong>P2Y&lt;sb&gt;12&lt;/sb&gt; inhibitors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Clopidogrel loading dose followed by daily maintenance dose in patients unable to take aspirin</td>
<td>75 mg</td>
<td>I</td>
<td>B</td>
<td>(145)</td>
</tr>
<tr>
<td>• P2Y&lt;sb&gt;12&lt;/sb&gt; inhibitor, in addition to aspirin, for up to 12 mo for patients treated initially with either an early invasive or initial ischemia-guided strategy:</td>
<td>300-mg or 600-mg loading dose, then 75 mg/d</td>
<td>I</td>
<td>B</td>
<td>(143, 146)</td>
</tr>
<tr>
<td>– Clopidogrel</td>
<td>180-mg loading dose, then 90 mg BID</td>
<td></td>
<td></td>
<td>(147, 148)</td>
</tr>
<tr>
<td>– Ticagrelor*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• P2Y&lt;sb&gt;12&lt;/sb&gt; inhibitor therapy (clopidogrel, prasugrel, or ticagrelor) continued for at least 12 mo in post–PCI patients treated with coronary stents</td>
<td>N/A</td>
<td>I</td>
<td>B</td>
<td>(147, 169-172)</td>
</tr>
<tr>
<td>• Ticagrelor in preference to clopidogrel for patients treated with an early invasive or ischemia-guided strategy</td>
<td>N/A</td>
<td></td>
<td>Ila</td>
<td>(147, 148)</td>
</tr>
<tr>
<td><strong>GP IIb/IIIa inhibitors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• GP IIb/IIIa inhibitor in patients treated with an early invasive strategy and DAPT with intermediate/high-risk features (e.g., positive troponin)</td>
<td>Preferred options are eptifibatide or tirofiban</td>
<td>Ila</td>
<td>B</td>
<td>(41, 149, 150)</td>
</tr>
<tr>
<td><strong>Parenteral anticoagulant and fibrinolytic therapy</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• SC enoxaparin for duration of hospitalization or until PCI is performed</td>
<td>1 mg/kg SC every 12 h (reduce dose to 1 mg/kg/d SC in patients with CrCl &lt;30 mL/min)</td>
<td>I</td>
<td>A</td>
<td>(151-153)</td>
</tr>
<tr>
<td>• Bivalirudin until diagnostic angiography or PCI is performed in patients with early invasive strategy only</td>
<td>Loading dose 0.10 mg/kg loading dose followed by 0.25 mg/kg/h</td>
<td>I</td>
<td>B</td>
<td>(146, 147, 154, 155)</td>
</tr>
<tr>
<td>• SC fondaparinux for the duration of hospitalization or until PCI is performed</td>
<td>2.5 mg SC daily</td>
<td>I</td>
<td>B</td>
<td>(156-158)</td>
</tr>
<tr>
<td>• Administer additional anticoagulant with anti-IIa activity if PCI is performed while patient is on fondaparinux</td>
<td>N/A</td>
<td>I</td>
<td>B</td>
<td>(157-159)</td>
</tr>
<tr>
<td>• IV UFH for 48 h or until PCI is performed</td>
<td>Initial loading dose 60 IU/kg (max 4,000 IU) with initial infusion 12 IU/kg/h (max 1,000)</td>
<td>I</td>
<td>B</td>
<td>(160-166)</td>
</tr>
</tbody>
</table>
IV fibrinolytic treatment not recommended in patients with NSTE-ACS

N/A

III: Harm

A

(167, 168)

*The recommended maintenance dose of aspirin to be used with ticagrelor is 81 mg daily (144).

aPTT indicates activated partial thromboplastin time; BID, twice daily; COR, Class of Recommendation; CrCl, creatinine clearance; DAPT, dual antiplatelet therapy; GP, glycoprotein; IV, intravenous; LOE, Level of Evidence; max, maximum; N/A, not available; NSTE-ACS, non–ST-elevation acute coronary syndromes; PCI, percutaneous coronary intervention; SC, subcutaneous; and UFH, unfractionated heparin.

4.4. Ischemia-Guided Strategy Versus Early Invasive Strategies

See Figure 3 for the management algorithm for ischemia-guided versus early invasive strategy.
Amsterdam EA, et al.
2014 AHA/ACC NSTE-ACS Executive Summary

Figure 3. Algorithm for Management of Patients With Definite or Likely NSTE-ACS*

*See corresponding full-sentence recommendations and their explanatory footnotes.
†In patients who have been treated with fondaparinux (as upfront therapy) who are undergoing PCI, an additional anticoagulant with anti-IIa activity should be administered at the time of PCI because of the risk of catheter thrombosis.

ASA indicates aspirin; CABG, coronary artery bypass graft; cath, catheter; COR, Class of Recommendation; DAPT, dual-antiplatelet therapy; GPI, glycoprotein IIb/IIIa inhibitor; LOE, Level of Evidence; NSTE-ACS, non–ST-elevation acute coronary syndrome; PCI, percutaneous coronary intervention; pts, patients; and UFH, unfractionated heparin.

4.4.1. Early Invasive and Ischemia-Guided Strategies

For definitions of invasive and ischemia-guided strategies, see Table 8.

Class I
1. An urgent/immediate invasive strategy (diagnostic angiography with intent to perform revascularization if appropriate based on coronary anatomy) is indicated in patients (men and women) with NSTE-ACS who have refractory angina or hemodynamic or electrical instability (without serious comorbidities or contraindications to such procedures) (40, 42, 173, 174). (Level of Evidence: A)
2. An early invasive strategy (diagnostic angiography with intent to perform revascularization if appropriate based on coronary anatomy) is indicated in initially stabilized patients with NSTE-ACS (without serious comorbidities or contraindications to such procedures) who have an elevated risk for clinical events (Table 8) (40, 42, 173-177). (Level of Evidence: B)

Class IIa
1. It is reasonable to choose an early invasive strategy (within 24 hours of admission) over a delayed invasive strategy (within 24 to 72 hours) for initially stabilized high-risk patients with NSTE-ACS. For those not at high/intermediate risk, a delayed invasive approach is reasonable (173). (Level of Evidence: B)

Class IIb
1. In initially stabilized patients, an ischemia-guided strategy may be considered for patients with NSTE-ACS (without serious comorbidities or contraindications to this approach) who have an elevated risk for clinical events (174, 175, 177). (Level of Evidence: B)
2. The decision to implement an ischemia-guided strategy in initially stabilized patients (without serious comorbidities or contraindications to this approach) may be reasonable after considering clinician and patient preference. (Level of Evidence: C)

Class III: No Benefit
1. An early invasive strategy (i.e., diagnostic angiography with intent to perform revascularization) is not recommended in patients with:
   a. Extensive comorbidities (e.g., hepatic, renal, pulmonary failure, cancer), in whom the risks of revascularization and comorbid conditions are likely to outweigh the benefits of revascularization. (Level of Evidence: C)
   b. Acute chest pain and a low likelihood of ACS (Level of Evidence: C) who are troponin-negative, especially women (178). (Level of Evidence: B)

Table 8. Factors Associated With Appropriate Selection of Early Invasive Strategy or Ischemia-Guided Strategy in Patients With NSTE-ACS

<table>
<thead>
<tr>
<th>Immediate invasive (within 2 h)</th>
<th>Refractory angina</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Signs or symptoms of HF or new or worsening mitral regurgitation</td>
</tr>
<tr>
<td></td>
<td>Hemodynamic instability</td>
</tr>
<tr>
<td></td>
<td>Recurrent angina or ischemia at rest or with low-level activities despite intensive medical therapy</td>
</tr>
</tbody>
</table>
Sustained VT or VF

Ischemia-guided strategy

<table>
<thead>
<tr>
<th>Low-risk score (e.g., TIMI [0 or 1], GRACE [&lt;109])</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low-risk Tn-negative female patients</td>
</tr>
<tr>
<td>Patient or clinician preference in the absence of high-risk features</td>
</tr>
</tbody>
</table>

Early invasive (within 24 h)

<table>
<thead>
<tr>
<th>None of the above, but GRACE risk score &gt;140</th>
</tr>
</thead>
<tbody>
<tr>
<td>Temporal change in Tn (Section 3.4)</td>
</tr>
<tr>
<td>New or presumably new ST depression</td>
</tr>
</tbody>
</table>

Delayed invasive (within 25–72 h)

| None of the above but diabetes mellitus       |
| Reduced LV systolic function (EF <0.40)       |
| Early postinfarction angina                   |
| PCI within 6 mo                               |
| Prior CABG                                   |
| GRACE risk score 109–140; TIMI score ≥2       |

CABG indicates coronary artery bypass graft; EF, ejection fraction; GFR, glomerular filtration rate; GRACE, Global Registry of Acute Coronary Events; HF, heart failure; LV, left ventricular; NSTE-ACS, non–ST-elevation acute coronary syndrome; PCI, percutaneous coronary intervention; TIMI, Thrombolysis In Myocardial Infarction; Tn, troponin; VF, ventricular fibrillation; and VT, ventricular tachycardia.

4.5. Risk Stratification Before Discharge for Patients With an Ischemia-Guided Strategy of NSTE-ACS

Class I

1. Noninvasive stress testing is recommended in low- and intermediate-risk patients who have been free of ischemia at rest or with low-level activity for a minimum of 12 to 24 hours (179-183). *(Level of Evidence: B)*
2. Treadmill exercise testing is useful in patients able to exercise in whom the ECG is free of resting ST changes that may interfere with interpretation (179-182). *(Level of Evidence: C)*
3. Stress testing with an imaging modality should be used in patients who are able to exercise but have ST changes on resting ECG that may interfere with interpretation. In patients undergoing a low-level exercise test, an imaging modality can add prognostic information (179-182). *(Level of Evidence: B)*
4. Pharmacological stress testing with imaging is recommended when physical limitations preclude adequate exercise stress. *(Level of Evidence: C)*
5. A noninvasive imaging test is recommended to evaluate LV function in patients with definite ACS (179-182). *(Level of Evidence: C)*

5. Myocardial Revascularization: Recommendations

5.1. PCI—General Considerations

Class IIb

1. A strategy of multivessel PCI, in contrast to culprit lesion-only PCI, may be reasonable in patients undergoing coronary revascularization as part of treatment for NSTE-ACS (169, 184-189). *(Level of Evidence: B)*

5.1.1. PCI—Oral and Intravenous Antiplatelet Agents

Class I

1. Patients already taking daily aspirin before PCI should take 81 mg to 325 mg non–enteric-coated aspirin before PCI (27, 190-192). *(Level of Evidence: B)*
2. Patients not on aspirin therapy should be given non-enteric-coated aspirin 325 mg as soon as possible before PCI (27, 190-192). (Level of Evidence: B)
3. After PCI, aspirin should be continued indefinitely at a dose of 81 mg to 325 mg daily (28, 142, 193). (Level of Evidence: B)
4. A loading dose of a P2Y₁₂ receptor inhibitor should be given before the procedure in patients undergoing PCI with stenting (27, 147, 170, 172, 194-197). (Level of Evidence: A)
   a. Clopidogrel: 600 mg (170, 194-196, 198-200) (Level of Evidence: B) or
   b. Prasugrel: 60 mg (172) (Level of Evidence: B) or
   c. Ticagrelor: 180 mg (147) (Level of Evidence: B)
5. In patients with NSTE-ACS and high-risk features (e.g., elevated troponin) not adequately pretreated with clopidogrel or ticagrelor, it is useful to administer a GP IIb/IIIa inhibitor (abciximab, double-bolus eptifibatide, or high-dose bolus tirofiban) at the time of PCI (201-204). (Level of Evidence: A)
6. In patients receiving a stent (bare-metal stent or drug-eluting stent [DES]) during PCI for NSTE-ACS, P2Y₁₂ inhibitor therapy should be given for at least 12 months (169). Options include:
   a. Clopidogrel: 75 mg daily (170, 171) (Level of Evidence: B) or
   b. Prasugrel: 10 mg daily (172) (Level of Evidence: B) or
   c. Ticagrelor: 90 mg twice daily (147) (Level of Evidence: B)

Class IIa
1. It is reasonable to choose ticagrelor over clopidogrel for P2Y₁₂ inhibition treatment in patients with NSTE-ACS treated with an early invasive strategy and/or coronary stenting (147, 148). (Level of Evidence: B)
2. It is reasonable to choose prasugrel over clopidogrel for P2Y₁₂ treatment in patients with NSTE-ACS who undergo PCI who are not at high risk of bleeding complications (172, 205). (Level of Evidence: B)
3. In patients with NSTE-ACS and high-risk features (e.g., elevated troponin) treated with UFH and adequately pretreated with clopidogrel, it is reasonable to administer a GP IIb/IIIa inhibitor (abciximab, double-bolus eptifibatide, or high-dose bolus tirofiban) at the time of PCI (206-208). (Level of Evidence: B)
4. After PCI, it is reasonable to use 81 mg per day of aspirin in preference to higher maintenance doses (170, 190, 209-212). (Level of Evidence: B)
5. If the risk of morbidity from bleeding outweighs the anticipated benefit of a recommended duration of P2Y₁₂ inhibitor therapy after stent implantation, earlier discontinuation (e.g., <12 months) of P2Y₁₂ inhibitor therapy is reasonable (169). (Level of Evidence: C)

Class IIb
1. Continuation of DAPT beyond 12 months may be considered in patients undergoing stent implantation. (Level of Evidence: C)

Class III: Harm
1. Prasugrel should not be administered to patients with a prior history of stroke or transient ischemic attack (172). (Level of Evidence: B)

5.1.1.1. PCI—GP IIb/IIIa Inhibitors

---

¹ Patients should receive a loading dose of prasugrel provided that they were not pretreated with another P2Y₁₂ receptor inhibitor.
² The recommended maintenance dose of aspirin to be used with ticagrelor is 81 mg daily (144).
Amsterdam EA, et al.
2014 AHA/ACC NSTE-ACS Executive Summary

Class I
1. In patients with NSTE-ACS and high-risk features (e.g., elevated troponin) and not adequately pretreated with clopidogrel or ticagrelor, it is useful to administer a GP IIb/IIIa inhibitor (abciximab, double-bolus eptifibatide, or high-dose bolus tirofiban) at the time of PCI (201-204). (Level of Evidence: A)

Class IIa
1. In patients with NSTE-ACS and high-risk features (e.g., elevated troponin) treated with UFH and adequately pretreated with clopidogrel, it is reasonable to administer a GP IIb/IIIa inhibitor (abciximab, double-bolus eptifibatide, or high-dose bolus tirofiban) at the time of PCI (206, 207). (Level of Evidence: B)

5.1.2. Anticoagulant Therapy in Patients Undergoing PCI

See Table 9 for dosing information on dosing of parenteral anticoagulants during PCI.

Class I
1. An anticoagulant should be administered to patients with NSTE-ACS undergoing PCI to reduce the risk of intracoronary and catheter thrombus formation. (Level of Evidence: C)
2. Intravenous UFH is useful in patients with NSTE-ACS undergoing PCI. (Level of Evidence: C)
3. Bivalirudin is useful as an anticoagulant with or without prior treatment with UFH in patients with NSTE-ACS undergoing PCI (154, 213-217). (Level of Evidence: B)
4. An additional dose of 0.3 mg/kg IV enoxaparin should be administered at the time of PCI to patients with NSTE-ACS who have received fewer than 2 therapeutic subcutaneous doses (e.g., 1 mg/kg SC) or received the last subcutaneous enoxaparin dose 8 to 12 hours before PCI (152, 218-222). (Level of Evidence: B)
5. If PCI is performed while the patient is on fondaparinux, an additional 85 IU/kg of UFH should be given intravenously immediately before PCI because of the risk of catheter thrombosis (60 IU/kg IV if a GP IIb/IIIa inhibitor used with UFH dosing based on the target-activated clotting time) (27, 157-159, 223). (Level of Evidence: B)
6. In patients with NSTE-ACS, anticoagulant therapy should be discontinued after PCI unless there is a compelling reason to continue such therapy. (Level of Evidence: C)

Class IIa
1. In patients with NSTE-ACS undergoing PCI who are at high risk of bleeding, it is reasonable to use bivalirudin monotherapy in preference to the combination of UFH and a GP IIb/IIIa receptor antagonist (154, 215). (Level of Evidence: B)

Class IIb
1. Performance of PCI with enoxaparin may be reasonable in patients treated with upstream subcutaneous enoxaparin for NSTE-ACS (27, 152, 218-221, 224, 225). (Level of Evidence: B)

Class III: Harm
1. Fondaparinux should not be used as the sole anticoagulant to support PCI in patients with NSTE-ACS due to an increased risk of catheter thrombosis (27, 157-159). (Level of Evidence: B)

Table 9. Dosing of Parenteral Anticoagulants During PCI

<table>
<thead>
<tr>
<th>Drug*</th>
<th>In Patients Who Have Received Prior Anticoagulant Therapy</th>
<th>In Patients Who Have Not Received Prior Anticoagulant Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enoxaparin</td>
<td>• For prior treatment with enoxaparin, if last SC dose was administered 8–12 h earlier or if &lt;2 therapeutic SC doses of enoxaparin have been administered, an IV dose of enoxaparin 0.3 mg/kg should be given</td>
<td>• 0.5 mg/kg–0.75 mg/kg IV loading dose</td>
</tr>
</tbody>
</table>

Downloaded From: http://content.onlinejacc.org/ by Bruno Migueletto on 09/29/2014
Amsterdam EA, et al.  
2014 AHA/ACC NSTE-ACS Executive Summary

- If the last SC dose was administered within prior 8 h, no additional enoxaparin should be given

| Bivalirudin | For patients who have received UFH, wait 30 min, then give 0.75 mg/kg IV loading dose, then 1.75 mg/kg/h IV infusion  
For patients already receiving bivalirudin infusion, give additional loading dose 0.5 mg/kg and increase infusion to 1.75 mg/kg/h during PCI  
0.75 mg/kg loading dose, 1.75 mg/kg/h IV infusion |
| --- | --- |
| Fondaparinux | For prior treatment with fondaparinux, administer additional IV treatment with anticoagulant possessing anti-IIa activity, considering whether GPI receptor antagonists have been administered  
N/A |
| UFH | IV GPI planned: additional UFH as needed (e.g., 2,000–5,000 U) to achieve ACT of 200–250 s  
No IV GPI planned: additional UFH as needed (e.g., 2,000–5,000 U) to achieve ACT of 250–300 s for HemoTec, 300–350 s for Hemochron  
IV GPI planned: 50–70 U/kg loading dose to achieve ACT of 200–250 s  
No IV GPI planned: 70–100 U/kg loading dose to achieve target ACT of 250–300 s for HemoTec, 300–350 s for Hemochron |

*Drugs presented in order by the COR and then the LOE as noted in the Preamble. When more than 1 drug exists within the same LOE, and there are no comparative data, then the drugs are listed alphabetically.

ACT indicates activated clotting time; GPI, glycoprotein IIb/IIIa inhibitor; IV, intravenous; N/A, not applicable; PCI, percutaneous coronary intervention; SC, subcutaneous; and UFH, unfractionated heparin. Modified from Levine et al. (27).

5.2. Timing of Urgent Coronary Artery Bypass Graft in Patients With NSTE-ACS in Relation to Use of Antiplatelet Agents

Class I

1. Non–enteric-coated aspirin (81 mg to 325 mg daily) should be administered preoperatively to patients undergoing coronary artery bypass graft (CABG) (226-228). *(Level of Evidence: B)*

2. In patients referred for elective CABG, clopidogrel and ticagrelor should be discontinued for at least 5 days before surgery (24, 229-231) *(Level of Evidence: B)* and prasugrel for at least 7 days before surgery (9, 232). *(Level of Evidence: C)*

3. In patients referred for urgent CABG, clopidogrel and ticagrelor should be discontinued for at least 24 hours to reduce major bleeding (9, 230, 233-235). *(Level of Evidence: B)*

4. In patients referred for CABG, short-acting intravenous GP IIb/IIIa inhibitors (eptifibatide or tirofiban) should be discontinued for at least 2 to 4 hours before surgery (236, 237) and abciximab for at least 12 hours before to limit blood loss and transfusion (238). *(Level of Evidence: B)*

Class IIb

1. In patients referred for urgent CABG, it may be reasonable to perform surgery less than 5 days after clopidogrel or ticagrelor has been discontinued and less than 7 days after prasugrel has been discontinued. *(Level of Evidence: C)*

6. Late Hospital Care, Hospital Discharge, and Posthospital Discharge Care: Recommendations

6.1. Medical Regimen and Use of Medications at Discharge
Class I
1. Medications required in the hospital to control ischemia should be continued after hospital discharge in patients with NSTE-ACS who do not undergo coronary revascularization, patients with incomplete or unsuccessful revascularization, and patients with recurrent symptoms after revascularization. Titration of the doses may be required (239, 240). (Level of Evidence: C)
2. All patients who are post–NSTE-ACS should be given sublingual or spray nitroglycerin with verbal and written instructions for its use (241). (Level of Evidence: C)
3. Before hospital discharge, patients with NSTE-ACS should be informed about symptoms of worsening myocardial ischemia and MI and should be given verbal and written instructions about how and when to seek emergency care for such symptoms (241). (Level of Evidence: C)
4. Before hospital discharge, patients who are post–NSTE-ACS and/or designated responsible caregivers should be provided with easily understood and culturally sensitive verbal and written instructions about medication type, purpose, dose, frequency, side effects, and duration of use (241). (Level of Evidence: C)
5. For patients who are post–NSTE-ACS and have initial angina lasting more than 1 minute, nitroglycerin (1 dose sublingual or spray) is recommended if angina does not subside within 3 to 5 minutes; call 9-1-1 immediately to access emergency medical services (241). (Level of Evidence: C)
6. If the pattern or severity of angina changes, suggesting worsening myocardial ischemia (e.g., pain is more frequent or severe or is precipitated by less effort or occurs at rest), patients should contact their clinician without delay to assess the need for additional treatment or testing (241). (Level of Evidence: C)
7. Before discharge, patients should be educated about modification of cardiovascular risk factors (240). (Level of Evidence: C)

6.2. Late Hospital and Posthospital Oral Antiplatelet Therapy

Class I
1. Aspirin should be continued indefinitely. The maintenance dose should be 81 mg daily in patients treated with ticagrelor and 81 mg to 325 mg daily in all other patients (142-144). (Level of Evidence: A)
2. In addition to aspirin, a P2Y₁₂ inhibitor (either clopidogrel or ticagrelor) should be continued for up to 12 months in all patients with NSTE-ACS without contraindications who are treated with an ischemia-guided strategy. Options include:
   • Clopidogrel: 75 mg daily (143, 171) (Level of Evidence: B) or
   • Ticagrelor[1]: 90 mg twice daily (147, 148) (Level of Evidence: B)
3. In patients receiving a stent (bare-metal stent or DES) during PCI for NSTE-ACS, P2Y₁₂ inhibitor therapy should be given for at least 12 months (169). Options include:
   • Clopidogrel: 75 mg daily (170, 171) (Level of Evidence: B) or
   • Prasugrel[1]: 10 mg daily (172) (Level of Evidence: B) or
   • Ticagrelor[1]: 90 mg twice daily (147) (Level of Evidence: B)

Class IIa
1. It is reasonable to use an aspirin maintenance dose of 81 mg per day in preference to higher maintenance doses in patients with NSTE-ACS treated either invasively or with coronary stent implantation (27, 170, 190, 209-212). (Level of Evidence: B)
2. It is reasonable to choose ticagrelor over clopidogrel for maintenance P2Y₁₂ treatment in patients with NSTE-ACS treated with an early invasive strategy and/or PCI (147, 148). (Level of Evidence: B)

[1]Patients should receive a loading dose of prasugrel provided that they were not pretreated with another P2Y₁₂ receptor inhibitor.

[1]The recommended maintenance dose of aspirin to be used with ticagrelor is 81 mg daily (144).
3. It is reasonable to choose prasugrel over clopidogrel for maintenance P2Y<sub>12</sub> treatment in patients with NSTE-ACS who undergo PCI who are not at high risk for bleeding complications (172, 205). (Level of Evidence: B)

4. If the risk of morbidity from bleeding outweighs the anticipated benefit of a recommended duration of P2Y<sub>12</sub> inhibitor therapy after stent implantation, earlier discontinuation (e.g., <12 months) of P2Y<sub>12</sub> inhibitor therapy is reasonable (169). (Level of Evidence: C)

Class IIb
1. Continuation of DAPT beyond 12 months may be considered in patients undergoing stent implantation. (Level of Evidence: C)

6.3. Combined Oral Anticoagulant Therapy and Antiplatelet Therapy in Patients With NSTE-ACS

Class I
1. The duration of triple antithrombotic therapy with a vitamin K antagonist, aspirin, and a P2Y<sub>12</sub> receptor inhibitor in patients with NSTE-ACS should be minimized to the extent possible to limit the risk of bleeding. (Level of Evidence: C)

2. Proton pump inhibitors should be prescribed in patients with NSTE-ACS with a history of gastrointestinal bleeding who require triple antithrombotic therapy with a vitamin K antagonist, aspirin, and a P2Y<sub>12</sub> receptor inhibitor (27, 242, 243). (Level of Evidence: C)

Class IIa
1. Proton pump inhibitor use is reasonable in patients with NSTE-ACS without a known history of gastrointestinal bleeding who require triple antithrombotic therapy with a vitamin K antagonist, aspirin, and a P2Y<sub>12</sub> receptor inhibitor (27, 242, 243). (Level of Evidence: C)

Class IIb
1. Targeting oral anticoagulant therapy to a lower international normalized ratio (e.g., 2.0 to 2.5) may be reasonable in patients with NSTE-ACS managed with aspirin and a P2Y<sub>12</sub> inhibitor. (Level of Evidence: C)

6.4. Risk Reduction Strategies for Secondary Prevention

Class I
1. All eligible patients with NSTE-ACS should be referred to a comprehensive cardiovascular rehabilitation program either before hospital discharge or during the first outpatient visit (244-247). (Level of Evidence: B)

2. The pneumococcal vaccine is recommended for patients 65 years of age and older and in high-risk patients with cardiovascular disease (248-250). (Level of Evidence: B)

3. Patients should be educated about appropriate cholesterol management, blood pressure (BP), smoking cessation, and lifestyle management (16, 17, 19). (Level of Evidence: C)

4. Patients who have undergone PCI or CABG derive benefit from risk factor modification and should receive counseling that revascularization does not obviate the need for lifestyle changes (251). (Level of Evidence: C)

5. Before hospital discharge, the patient’s need for treatment of chronic musculoskeletal discomfort should be assessed, and a stepped-care approach should be used for selection of treatments. Pain treatment before consideration of NSAIDs should begin with acetaminophen, nonacetylated salicylates, tramadol, or small doses of narcotics if these medications are not adequate (18, 252). (Level of Evidence: C)
Amsterdam EA, et al.  
2014 AHA/ACC NSTE-ACS Executive Summary

Class IIa  
1. It is reasonable to use nonselective NSAIDs, such as naproxen, if initial therapy with acetaminophen, nonacetylated salicylates, tramadol, or small doses of narcotics is insufficient (252). (Level of Evidence: C)

Class IIb  
1. NSAIDs with increasing degrees of relative cyclooxygenase-2 selectivity may be considered for pain relief only for situations in which intolerable discomfort persists despite attempts at stepped-care therapy with acetaminophen, nonacetylated salicylates, tramadol, small doses of narcotics, or nonselective NSAIDs. In all cases, use of the lowest effective doses for the shortest possible time is encouraged (117, 118, 252, 253). (Level of Evidence: C)

Class III: No Benefit  
1. Antioxidant vitamin supplements (e.g., vitamins E, C, or beta carotene) should not be used for secondary prevention in patients with NSTE-ACS (254, 255). (Level of Evidence: A)
2. Folic acid, with or without vitamins B₆ and B₁₂, should not be used for secondary prevention in patients with NSTE-ACS (256, 257). (Level of Evidence: A)

Class III: Harm  
1. Hormone therapy with estrogen plus progestin, or estrogen alone, should not be given as new drugs for secondary prevention of coronary events to postmenopausal women after NSTE-ACS and should not be continued in previous users unless the benefits outweigh the estimated risks (18, 258-260). (Level of Evidence: A)
2. NSAIDs with increasing degrees of relative cyclooxygenase-2 selectivity should not be administered to patients with NSTE-ACS and chronic musculoskeletal discomfort when therapy with acetaminophen, nonacetylated salicylates, tramadol, small doses of narcotics, or nonselective NSAIDs provide acceptable pain relief (117, 118, 252, 253). (Level of Evidence: B)

6.5. Plan of Care for Patients With NSTE-ACS

Class I  
1. Posthospital systems of care designed to prevent hospital readmissions should be used to facilitate the transition to effective, coordinated outpatient care for all patients with NSTE-ACS (261-265). (Level of Evidence: B)
2. An evidence-based plan of care (e.g., GDMT) that promotes medication adherence, timely follow-up with the healthcare team, appropriate dietary and physical activities, and compliance with interventions for secondary prevention should be provided to patients with NSTE-ACS. (Level of Evidence: C)
3. In addition to detailed instructions for daily exercise, patients should be given specific instruction on activities (e.g., lifting, climbing stairs, yard work, and household activities) that are permissible and those to avoid. Specific mention should be made of resumption of driving, return to work, and sexual activity (247, 266, 267). (Level of Evidence: B)
4. An annual influenza vaccination is recommended for patients with cardiovascular disease (28, 268). (Level of Evidence: C)

7. Special Patient Groups: Recommendations  
See Table 10 for summary of recommendations for this section.

7.1. NSTE-ACS in Older Patients
Amsterdam EA, et al.
2014 AHA/ACC NSTE-ACS Executive Summary

Class I
1. Older patients** with NSTE-ACS should be treated with GDMT, an early invasive strategy, and
   revascularization as appropriate (269-273). (Level of Evidence: A)
2. Pharmacotherapy in older patients with NSTE-ACS should be individualized and dose adjusted
   by weight and/or CrCl to reduce adverse events caused by age-related changes in
   pharmacokinetics/dynamics, volume of distribution, comorbidities, drug interactions, and
   increased drug sensitivity (269, 274-276). (Level of Evidence: A)
3. Management decisions for older patients with NSTE-ACS should be patient centered, considering
   patient preferences/goals, comorbidities, functional and cognitive status, and life expectancy (269,
   277-279). (Level of Evidence: B)

Class IIa
1. Bivalirudin, rather than a GP IIb/IIIa inhibitor plus UFH, is reasonable in older patients with
   NSTE-ACS, both initially and at PCI, given similar efficacy but less bleeding risk (215, 280-282).
   (Level of Evidence: B)
2. It is reasonable to choose CABG over PCI in older patients** with NSTE-ACS who are
   appropriate candidates, particularly those with diabetes mellitus or complex 3-vessel CAD (e.g.,
   SYNTAX score >22), with or without involvement of the proximal left anterior descending artery,
   to reduce cardiovascular disease events and readmission and to improve survival (283-288). (Level
   of Evidence: B)

7.2. Heart Failure and Cardiogenic Shock

Class I
1. Patients with a history of HF and NSTE-ACS should be treated according to the same risk
   stratification guidelines and recommendations for patients without HF (15, 40-42, 52-58). (Level of
   Evidence: B)
2. Selection of a specific revascularization strategy should be based on the degree, severity, and
   extent of CAD; associated cardiac lesions; the extent of LV dysfunction; and the history of prior
   revascularization procedures (15, 173, 175, 177, 178, 289-292). (Level of Evidence: B)
3. Early revascularization is recommended in suitable patients with cardiogenic shock due to cardiac
   pump failure after NSTE-ACS (291, 293, 294). (Level of Evidence: B)

7.3. Diabetes Mellitus

Class I
1. Medical treatment in the acute phase of NSTE-ACS and decisions to perform stress testing,
   angiography, and revascularization should be similar in patients with and without diabetes
   mellitus (173, 176, 295). (Level of Evidence: A)

7.4. Post–CABG

Class I
1. Patients with prior CABG and NSTE-ACS should receive antiplatelet and anticoagulant therapy
   according to GDMT and should be strongly considered for early invasive strategy because of their
   increased risk (44, 45, 178, 290, 296, 297). (Level of Evidence: B)

**Those ≥75 years of age (see Section 7.1 in the full-text CPG).
7.5. Perioperative NSTE-ACS Related to Noncardiac Surgery

Class I
1. Patients who develop NSTE-ACS following noncardiac surgery should receive GDMT as recommended for patients in the general population but with the modifications imposed by the specific noncardiac surgical procedure and the severity of NSTE-ACS. (Level of Evidence: C)

2. In patients who develop NSTE-ACS after noncardiac surgery, management should be directed at the underlying cause. (Level of Evidence: C)

7.6. Chronic Kidney Disease

Class I
1. CrCl should be estimated in patients with NSTE-ACS, and doses of renally cleared medications should be adjusted according to the pharmacokinetic data for specific medications. (Level of Evidence: B)

2. Patients undergoing coronary and LV angiography should receive adequate hydration. (Level of Evidence: C)

Class IIa
1. An invasive strategy is reasonable in patients with mild (stage 2) and moderate (stage 3) CKD. (Level of Evidence: B)

7.7. Women

Class I
1. Women with NSTE-ACS should be managed with the same pharmacological therapy as that for men for acute care and for secondary prevention, with attention to weight and/or renally-calculated doses of antiplatelet and anticoagulant agents to reduce bleeding risk. (Level of Evidence: B)

2. Women with NSTE-ACS and high-risk features (e.g., troponin positive) should undergo an early invasive strategy. (Level of Evidence: A)

Class IIa
1. Myocardial revascularization is reasonable in pregnant women with NSTE-ACS if an ischemia-guided strategy is ineffective for management of life-threatening complications. (Level of Evidence: C)

Class III: No Benefit
1. Women with NSTE-ACS and low-risk features (see Section 3.3.1 in the full-text CPG) should not undergo early invasive treatment because of the lack of benefit and the possibility of harm. (Level of Evidence: B)

7.8. Anemia, Bleeding, and Transfusion

Class I
1. All patients with NSTE-ACS should be evaluated for the risk of bleeding. (Level of Evidence: C)

2. Anticoagulant and antiplatelet therapy should be weight-based where appropriate and should be adjusted when necessary for CKD to decrease the risk of bleeding in patients with NSTE-ACS. (Level of Evidence: B)
Class III: No Benefit

1. A strategy of routine blood transfusion in hemodynamically stable patients with NSTE-ACS and hemoglobin levels greater than 8 g/dL is not recommended (321-325). (Level of Evidence: B)

7.9. Cocaine and Methamphetamine Users

Class I

1. Patients with NSTE-ACS and a recent history of cocaine or methamphetamine use should be treated in the same manner as patients without cocaine- or methamphetamine-related NSTE-ACS. The only exception is in patients with signs of acute intoxication (e.g., euphoria, tachycardia, and/or hypertension) and beta-blocker use, unless patients are receiving coronary vasodilator therapy. (Level of Evidence: C)

Class IIa

1. Benzodiazepines alone or in combination with nitroglycerin are reasonable for management of hypertension and tachycardia in patients with NSTE-ACS and signs of acute cocaine or methamphetamine intoxication (326-329). (Level of Evidence: C)

Class III: Harm

1. Beta blockers should not be administered to patients with ACS with a recent history of cocaine or methamphetamine use who demonstrate signs of acute intoxication due to the risk of potentiating coronary spasm. (Level of Evidence: C)

7.10. Vasospastic (Prinzmetal) Angina

Class I

1. CCBs alone (330-334) or in combination with long-acting nitrates (332, 335) are useful to treat and reduce the frequency of vasospastic angina. (Level of Evidence: B)
2. Treatment with HMG-CoA reductase inhibitor (336, 337), cessation of tobacco use (338, 339), and additional atherosclerosis risk factor modification (339, 340) are useful in patients with vasospastic angina. (Level of Evidence: B)
3. Coronary angiography (invasive or noninvasive) is recommended in patients with episodic chest pain accompanied by transient ST elevation to rule out severe obstructive CAD. (Level of Evidence: C)

Class IIb

1. Provocative testing during invasive coronary angiography may be considered in patients with suspected vasospastic angina when clinical criteria and noninvasive testing fail to establish the diagnosis (341-344). (Level of Evidence: B)

7.11. ACS With Angiographically Normal Coronary Arteries

††Provocative testing during invasive coronary angiography (e.g., using ergonovine, acetylcholine, methylergonovine) is relatively safe, especially when performed in a controlled manner by experienced operators. However, sustained spasm, serious arrhythmias, and even death can also occur very infrequently. Therefore, provocative testing should be avoided in patients with significant left main disease, advanced 3-vessel disease, presence of high-grade obstructive lesions, significant valvular stenosis, significant LV systolic dysfunction, and advanced HF.
1. If coronary angiography reveals normal coronary arteries and endothelial dysfunction is suspected, invasive physiological assessment such as coronary flow reserve measurement may be considered (301, 345-348). (Level of Evidence: B)

7.12. Stress (Takotsubo) Cardiomyopathy

Class I
1. Stress (Takotsubo) cardiomyopathy should be considered in patients who present with apparent ACS and nonobstructive CAD at angiography. (Level of Evidence: C)
2. Imaging with ventriculography, echocardiography, or magnetic resonance imaging should be performed to confirm or exclude the diagnosis of stress (Takotsubo) cardiomyopathy (349-352). (Level of Evidence: B)
3. Patients should be treated with conventional agents (ACE inhibitors, beta blockers, aspirin, and diuretics) as otherwise indicated if hemodynamically stable. (Level of Evidence: C)
4. Anticoagulation should be administered in patients who develop LV thrombi. (Level of Evidence: C)

Class IIa
1. It is reasonable to use catecholamines for patients with symptomatic hypotension if outflow tract obstruction is not present. (Level of Evidence: C)
2. The use of an intra-aortic balloon pump is reasonable for patients with refractory shock. (Level of Evidence: C)
3. It is reasonable to use beta blockers and alpha-adrenergic agents in patients with outflow tract obstruction. (Level of Evidence: C)

Class IIb
1. Prophylactic anticoagulation may be considered to inhibit the development of LV thrombi. (Level of Evidence: C)

Table 10. Summary of Recommendations for Special Patient Groups

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>COR</th>
<th>LOE</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NSTE-ACS in older patients</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treat older patients (≥75 y of age) with GDMT, early invasive strategy, and revascularization as appropriate</td>
<td>I</td>
<td>A</td>
<td>(269-273)</td>
</tr>
<tr>
<td>Individualize pharmacotherapy in older patients, with dose adjusted by weight and/or CrCl to reduce adverse events caused by age-related changes in pharmacokinetics/dynamics, volume of distribution, comorbidity, drug interactions, and increased drug sensitivity</td>
<td>I</td>
<td>A</td>
<td>(269, 274-276)</td>
</tr>
<tr>
<td>Undertake patient-centered management for older patients, considering patient preferences/goals, comorbidities, functional and cognitive status, and life expectancy</td>
<td>I</td>
<td>B</td>
<td>(269, 277-279)</td>
</tr>
<tr>
<td>Bivalirudin rather than GP IIb/IIIa inhibitor plus UFH is reasonable for older patients (≥75 y of age), given similar efficacy but less bleeding risk</td>
<td>IIa</td>
<td>B</td>
<td>(215, 280-282)</td>
</tr>
<tr>
<td>It is reasonable to choose CABG over PCI in older patients, particularly those with DM or multivessel disease, because of the potential for improved survival and reduced CVD events</td>
<td>IIa</td>
<td>B</td>
<td>(283-288)</td>
</tr>
<tr>
<td><strong>HF and cardiogenic shock</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treat patients with a history of HF according to the same risk stratification guidelines and recommendations for patients without HF</td>
<td>I</td>
<td>B</td>
<td>(15, 40-42, 52-58)</td>
</tr>
<tr>
<td>Select a revascularization strategy based on the extent of CAD, associated cardiac lesions, LV dysfunction, and prior revascularization</td>
<td>I</td>
<td>B</td>
<td>(15, 173, 175, 177, 178, 289-292)</td>
</tr>
<tr>
<td>Recommend early revascularization for cardiogenic shock due to cardiac pump</td>
<td>I</td>
<td>B</td>
<td>(291, 293)</td>
</tr>
</tbody>
</table>
Amsterdam EA, et al.  
2014 AHA/ACC NSTE-ACS Executive Summary

<table>
<thead>
<tr>
<th>Failure</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DM</strong></td>
<td></td>
</tr>
<tr>
<td>Recommend medical treatment and decisions for testing and revascularization similar to those for patients without DM</td>
<td>I A (173, 176, 295)</td>
</tr>
<tr>
<td><strong>Post-CABG</strong></td>
<td></td>
</tr>
<tr>
<td>Recommend GDMT antiplatelet and anticoagulant therapy and early invasive strategy because of increased risk with prior CABG</td>
<td>I B (44, 45, 178, 290, 296, 297)</td>
</tr>
<tr>
<td><strong>Perioperative NSTE-ACS</strong></td>
<td></td>
</tr>
<tr>
<td>Administer GDMT to perioperative patients with limitations imposed by noncardiac surgery</td>
<td>I C (298, 299)</td>
</tr>
<tr>
<td>Direct management at underlying cause of perioperative NSTE-ACS</td>
<td>I C (22, 298-306)</td>
</tr>
<tr>
<td><strong>CKD</strong></td>
<td></td>
</tr>
<tr>
<td>Estimate CrCl and adjust doses of renally cleared medications according to pharmacokinetic data</td>
<td>I B (307, 308)</td>
</tr>
<tr>
<td>Administer adequate hydration to patients undergoing coronary and LV angiography</td>
<td>I C N/A</td>
</tr>
<tr>
<td>Invasive strategy is reasonable in patients with mild (stage 2) and moderate (stage 3) CKD</td>
<td>IIa B (307-310)</td>
</tr>
<tr>
<td><strong>Women</strong></td>
<td></td>
</tr>
<tr>
<td>Manage women with the same pharmacological therapy as that for men for acute care and secondary prevention, with attention to weight and/or renally calculated doses of antiplatelet and anticoagulant agents to reduce bleeding risk</td>
<td>I B (311-315)</td>
</tr>
<tr>
<td>Early invasive strategy is recommended in women with NSTE-ACS and high-risk features (troponin positive)</td>
<td>I A (178, 292, 316, 317)</td>
</tr>
<tr>
<td>Myocardial revascularization is reasonable for pregnant women if ischemia-guided strategy is ineffective for management of life-threatening complications</td>
<td>IIa C (318)</td>
</tr>
<tr>
<td>Women with low-risk features (Section 3.3.1 in the full-text CPG) should not undergo early invasive treatment because of lack of benefit and the possibility of harm</td>
<td>III: No Benefit B (178, 316, 317)</td>
</tr>
<tr>
<td><strong>Anemia, bleeding, and transfusion</strong></td>
<td></td>
</tr>
<tr>
<td>Evaluate all patients for risk of bleeding</td>
<td>I C N/A</td>
</tr>
<tr>
<td>Recommend that anticoagulant and antiplatelet therapy be weight-based where appropriate and adjusted for CKD to decrease the risk of bleeding</td>
<td>I B (276, 319, 320)</td>
</tr>
<tr>
<td>There is no benefit of routine blood transfusion in hemodynamically stable patients with hemoglobin levels &gt;8 g/dL</td>
<td>III: No Benefit B (321-325)</td>
</tr>
<tr>
<td><strong>Cocaine and methamphetamine users</strong></td>
<td></td>
</tr>
<tr>
<td>Manage patients with recent cocaine or methamphetamine use similarly to those without cocaine- or methamphetamine-related NSTE-ACS. The exception is in patients with signs of acute intoxication (e.g., euphoria, tachycardia, and hypertension) and beta-blocker use unless patients are receiving coronary vasodilator therapy.</td>
<td>I C N/A</td>
</tr>
<tr>
<td>It is reasonable to use benzodiazepines alone or in combination with NTG to manage hypertension and tachycardia and signs of acute cocaine or methamphetamine intoxication.</td>
<td>IIa C (326-329)</td>
</tr>
<tr>
<td>Do not administer beta blockers to patients with recent cocaine or methamphetamine use who have signs of acute intoxication due to risk of potentiating coronary spasm.</td>
<td>III: Harm C N/A</td>
</tr>
<tr>
<td><strong>Vasospastic (Prinzmetal) angina</strong></td>
<td></td>
</tr>
<tr>
<td>Recommend CCBs alone or in combination with nitrates</td>
<td>I B (330-335)</td>
</tr>
<tr>
<td>Recommend HMG-CoA reductase inhibitor, cessation of tobacco use, and atherosclerosis risk factor modification</td>
<td>I B (336-340)</td>
</tr>
<tr>
<td>Recommend coronary angiography (invasive or noninvasive) for episodic chest pain with transient ST elevation to detect severe CAD</td>
<td>I C N/A</td>
</tr>
<tr>
<td>Provocative testing during invasive coronary angiography* may be considered for</td>
<td>IIb B (341-344)</td>
</tr>
</tbody>
</table>
suspected vasospastic angina when clinical criteria and noninvasive assessment fail to determine diagnosis

**ACS with angiographically normal coronary arteries**

Invasive physiological assessment (coronary flow reserve measurement) may be considered with normal coronary arteries if endothelial dysfunction is suspected

<table>
<thead>
<tr>
<th></th>
<th>IIb</th>
<th>B</th>
<th>(301, 345-348)</th>
</tr>
</thead>
</table>

**Stress (Takotsubo) cardiomyopathy**

Consider stress-induced cardiomyopathy in patients with apparent ACS and nonobstructive CAD

<table>
<thead>
<tr>
<th></th>
<th>I</th>
<th>C</th>
<th>N/A</th>
</tr>
</thead>
</table>

Perform ventriculography, echocardiography, or MRI to confirm or exclude diagnosis

<table>
<thead>
<tr>
<th></th>
<th>I</th>
<th>B</th>
<th>(349-352)</th>
</tr>
</thead>
</table>

Treat with conventional agents (ACE inhibitors, beta blockers, aspirin, and diuretics) if hemodynamically stable

<table>
<thead>
<tr>
<th></th>
<th>I</th>
<th>C</th>
<th>N/A</th>
</tr>
</thead>
</table>

Administer anticoagulant therapy for LV thrombi

<table>
<thead>
<tr>
<th></th>
<th>I</th>
<th>C</th>
<th>N/A</th>
</tr>
</thead>
</table>

It is reasonable to administer catecholamines for symptomatic hypotension in the absence of LV outflow tract obstruction

<table>
<thead>
<tr>
<th></th>
<th>Iia</th>
<th>C</th>
<th>N/A</th>
</tr>
</thead>
</table>

It is reasonable to use IABP for refractory shock

<table>
<thead>
<tr>
<th></th>
<th>Iia</th>
<th>C</th>
<th>N/A</th>
</tr>
</thead>
</table>

It is reasonable to use beta blockers and alpha-adrenergic agents for LV outflow tract obstruction

<table>
<thead>
<tr>
<th></th>
<th>Iia</th>
<th>C</th>
<th>N/A</th>
</tr>
</thead>
</table>

Prophylactic anticoagulation may be considered to prevent LV thrombi

<table>
<thead>
<tr>
<th></th>
<th>IIb</th>
<th>C</th>
<th>N/A</th>
</tr>
</thead>
</table>

*Provocative testing during invasive coronary angiography (e.g., using ergonovine, acetylcholine, methylergonovine) is relatively safe, especially when performed in a controlled manner by experienced operators. However, sustained spasm, serious arrhythmias, and even death can also occur but very infrequently. Therefore, provocative tests should be avoided in patients with significant left main disease, advanced 3-vessel disease, presence of high-grade obstructive lesions, significant valvular stenosis, significant LV systolic dysfunction, and advanced HF.*

ACE indicates angiotensin-converting enzyme; ACS, acute coronary syndrome; CABG, coronary artery bypass graft; CAD, coronary artery disease; CCB, calcium channel blocker; CKD, chronic kidney disease; COR, Class of Recommendation; CPG, clinical practice guideline; CrCl, creatinine clearance; CVD, cardiovascular disease; DM, diabetes mellitus; GDMT, guideline-directed medical therapy; GP, glycoprotein; HF, heart failure; IABP, intra-aortic balloon pump; LOE, Level of Evidence; LV, left ventricular; MRI, magnetic resonance imaging; N/A, not available; NSTE-ACS, non-ST-elevation acute coronary syndrome; NTG, nitroglycerin; PCI, percutaneous coronary intervention; and UFH, unfractionated heparin.

8. Quality of Care and Outcomes for ACS—Use of Performance Measures and Registries: Recommendation

Class IIa

1. Participation in a standardized quality-of-care data registry designed to track and measure outcomes, complications, and performance measures can be beneficial in improving the quality of NSTE-ACS care (353-361). (*Level of Evidence: B*)

9. Summary and Evidence Gaps

Despite landmark advances in the care of patients with NSTE-ACS since the publication of the 2007 UA/NSTEMI CPG (362), many emerging diagnostic and therapeutic strategies have posed new challenges. There is general acceptance of an early invasive strategy for patients with NSTE-ACS in whom significant coronary vascular obstruction has been precisely quantified. Low-risk patients with NSTE-ACS are documented to benefit substantially from GDMT, but this is often suboptimally used. Advances in noninvasive testing have the potential to identify patients with NSTE-ACS who are at intermediate risk and are candidates for invasive versus medical therapy.
Amsterdam EA, et al.  
2014 AHA/ACC NSTE-ACS Executive Summary

Newer, more potent antiplatelet agents in addition to anticoagulant therapy are indicated irrespective of initial treatment strategy. Evidence-based decisions will require comparative-effectiveness studies of available and novel agents. The paradox of newer and more potent antithrombotic and anticoagulant drugs that reduce major adverse cardiac outcomes but increase bleeding risk occurs with greater frequency in patients with atrial fibrillation. Patients with atrial fibrillation who develop NSTE-ACS and receive a coronary stent are the population at risk from triple anticoagulant/antiplatelet therapy. This regimen has been reported to be safely modified by elimination of aspirin, a finding that requires confirmation.

Among the most rapidly evolving areas in NSTE-ACS diagnosis is the use of cardiac troponin, the preferred biomarker of myocardial necrosis. Although a truly high-sensitivity cardiac troponin is not available in the United States at the time this CPG was prepared, the sensitivity of contemporary assays continues to increase. This change is accompanied by higher rates of elevated cardiac troponin unrelated to coronary plaque rupture. The diagnostic quandary posed by these findings necessitates investigation to elucidate the optimal utility of this advanced biomarker. A promising approach to improve the diagnostic accuracy for detecting myocardial necrosis is measurement of absolute cardiac troponin change, which may be more accurate than the traditional analysis of relative alterations.

Special populations are addressed in this CPG, the most numerous of which are older persons and women. More than half of the mortality in NSTE-ACS occurs in older patients, and this high-risk cohort will increase as our population ages. An unmet need is to more clearly distinguish which older patients are candidates for an ischemia-guided strategy compared with an early invasive management strategy. An appreciable number of patients with NSTE-ACS have angiographically normal or nonobstructive CAD, a group in which women predominate. Their prognosis is not benign and the multiple mechanisms of ACS postulated for these patients remain largely speculative. Clinical advances are predicated on clarification of the pathophysiology of this challenging syndrome.

A fundamental aspect of all CPGs is that these carefully developed, evidence-based documents cannot encompass all clinical circumstances, nor can they replace the judgment of individual physicians in management of each patient. The science of medicine is rooted in evidence, and the art of medicine is based on the application of this evidence to the individual patient. This CPG has adhered to these principles for optimal management of patients with NSTE-ACS.
Amsterdam EA, et al.  
2014 AHA/ACC NSTE-ACS Executive Summary

Presidents and Staff

American College of Cardiology  
Patrick O’Gara, MD, FACC, President  
Shalom Jacobovitz, Chief Executive Officer  
William J. Oetgen, MD, MBA, FACC, Executive Vice President, Science, Education, and Quality  
Amelia Scholtz, PhD, Publications Manager, Clinical Policy and Pathways

American College of Cardiology/American Heart Association  
Lisa Bradfield, CAE, Director, Science and Clinical Policy  
Emily Cottrell, MA, Quality Assurance Specialist, Science and Clinical Policy  
Alexa Papaila, Specialist, Science and Clinical Policy

American Heart Association  
Elliott Antman, MD, FAHA, President  
Nancy Brown, Chief Executive Officer  
Rose Marie Robertson, MD, FAHA, Chief Science Officer  
Gayle R. Whitman, PhD, RN, FAHA, FAAN, Senior Vice President, Office of Science Operations  
Marco Di Buono, PhD, Vice President, Science, Research, and Professional Education, Office of Science Operations  
Jody Hundley, Production Manager, Scientific Publications, Office of Science Operations

Key Words: ACC/AHA Clinical Practice Guidelines • acute coronary syndrome • angina, unstable • antiplatelet agents • coronary artery bypass graft • electrocardiography • ischemia • myocardial infarction • percutaneous coronary intervention • troponin.
### Appendix 1. Author Relationships With Industry and Other Entities (Relevant)—2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes

<table>
<thead>
<tr>
<th>Committee Member</th>
<th>Employment</th>
<th>Consultant</th>
<th>Speakers Bureau</th>
<th>Ownership/Partnership/Principal</th>
<th>Personal Research</th>
<th>Institutional, Organizational, or Other Financial Benefit</th>
<th>Expert Witness</th>
<th>Voting Recusals by Section*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ezra A. Amsterdam (Chair)</strong></td>
<td>University of California (Davis) Medical Center, Division of Cardiology—Professor</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td><strong>Nanette K. Wenger (Vice Chair)</strong></td>
<td>Emory University, School of Medicine—Professor of Medicine (Cardiology)</td>
<td>• Abbott • Amgen • AstraZeneca • Gilead Sciences† • Janssen Pharmaceuticals • Medtronic • Merck • Pfizer</td>
<td>None</td>
<td>None</td>
<td>• Abbott† • Eli Lilly† • Gilead Sciences† • Merck • Pfizer†</td>
<td>None</td>
<td>None</td>
<td>All sections except 3.1.1, 3.4, 5.2, 6.3.1, 6.3.2, 6.3.6, 7.5, 7.6, 7.8, and 8.</td>
</tr>
<tr>
<td><strong>Ralph G. Brindis</strong></td>
<td>University of California, San Francisco—Department of Medicine and the Phillip R. Lee Institute for Health Policy Studies—Clinical Professor of Medicine</td>
<td>None</td>
<td>• Volcano Corp.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td><strong>Donald E. Casey, Jr</strong></td>
<td>Atlantic Health—Vice President of Health and Chief Medical Officer</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td><strong>Theodore G. Ganiats</strong></td>
<td>University of California, San Diego School of Medicine—Executive Director of Health Services Research Center</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td><strong>David R.</strong></td>
<td>Mayo Clinic—</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Name</td>
<td>Institution</td>
<td>Consultant(s)</td>
<td>Acknowledgments</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Allan S. Jaffe</td>
<td>Mayo Clinic, Cardiovascular Division—Professor of Medicine</td>
<td>• Abbott&lt;br&gt;• Alere&lt;br&gt;• Amgen&lt;br&gt;• Beckman-Coulter&lt;br&gt;• Critical Diagnostics&lt;br&gt;• ET Healthcare&lt;br&gt;• Ortho Clinical&lt;br&gt;Diagnostic&lt;br&gt;• Radiometer&lt;br&gt;• Roche‡&lt;br&gt;• Thermo-Fisher‡&lt;br&gt;• Trinity</td>
<td>All sections except 3.1, 3.1.1, 3.3, 4.1.2.1-4.2, 4.3.1, 4.3.2, 4.5, 5.1, 5.2, 6.2.1, 6.3.1, 6.3.3, 6.3.6, 7.2.2, 7.5, 7.6, and 8.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hani Jneid</td>
<td>Baylor College of Medicine—The Michael E. DeBakey VA Medical Center—Assistant Professor of Medicine</td>
<td>None&lt;br&gt;• Abbott&lt;br&gt;• General Electric&lt;br&gt;• Ikaria&lt;br&gt;• Prevencio&lt;br&gt;• Sanofi-aventis&lt;br&gt;• Wellpoint/Anthem</td>
<td>None&lt;br&gt;• Astellas&lt;br&gt;• AstraZeneca&lt;br&gt;• Eli Lilly‡&lt;br&gt;• Merck‡&lt;br&gt;• Novartis‡</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rosemary F. Kelly</td>
<td>University of Minnesota—Professor of Surgery, VA Medical Center—Chief, Cardiothoracic Surgery</td>
<td>None&lt;br&gt;• Abbott&lt;br&gt;• General Electric&lt;br&gt;• Ikaria&lt;br&gt;• Prevencio&lt;br&gt;• Sanofi-aventis&lt;br&gt;• Wellpoint/Anthem</td>
<td>None&lt;br&gt;• Astellas&lt;br&gt;• AstraZeneca&lt;br&gt;• Eli Lilly‡&lt;br&gt;• Merck‡&lt;br&gt;• Novartis‡</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Michael C. Kontos</td>
<td>Virginia Commonwealth University, Pauley Heart Center—Medical Director, Coronary Intensive Care Unit; Associate Professor, Internal Medicine</td>
<td>• Astellas&lt;br&gt;• General Electric&lt;br&gt;• Ikaria&lt;br&gt;• Prevencio&lt;br&gt;• Sanofi-aventis&lt;br&gt;• Wellpoint/Anthem</td>
<td>None&lt;br&gt;• Astellas&lt;br&gt;• AstraZeneca&lt;br&gt;• Eli Lilly‡&lt;br&gt;• Merck‡&lt;br&gt;• Novartis‡</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glenn N. Levine</td>
<td>Baylor College of Medicine—Professor of Medicine; Director, Cardiac Care Unit</td>
<td>None&lt;br&gt;• Abbott&lt;br&gt;• General Electric&lt;br&gt;• Ikaria&lt;br&gt;• Prevencio&lt;br&gt;• Sanofi-aventis&lt;br&gt;• Wellpoint/Anthem</td>
<td>None&lt;br&gt;• Astellas&lt;br&gt;• AstraZeneca&lt;br&gt;• Eli Lilly‡&lt;br&gt;• Merck‡&lt;br&gt;• Novartis‡</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Philip R. Liebson</td>
<td>Rush University Medical Center—</td>
<td>None&lt;br&gt;• Abbott&lt;br&gt;• General Electric&lt;br&gt;• Ikaria&lt;br&gt;• Prevencio&lt;br&gt;• Sanofi-aventis&lt;br&gt;• Wellpoint/Anthem</td>
<td>None&lt;br&gt;• Astellas&lt;br&gt;• AstraZeneca&lt;br&gt;• Eli Lilly‡&lt;br&gt;• Merck‡&lt;br&gt;• Novartis‡</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Amsterdam EA, et al.
2014 AHA/ACC NSTE-ACS Executive Summary

<table>
<thead>
<tr>
<th>McMullan-Eybel Chair of Excellence in Clinical Cardiology and Professor of Medicine and Preventive Medicine</th>
<th>None</th>
<th>None</th>
<th>None</th>
<th>None</th>
<th>None</th>
<th>None</th>
<th>None</th>
<th>None</th>
</tr>
</thead>
<tbody>
<tr>
<td>Debabrata Mukherjee</td>
<td>Texas Tech University Health Sciences Center—Chief, Cardiovascular Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Eric D. Peterson</td>
<td>Duke University Medical Center—Fred Cobb, MD, Distinguished Professor of Medicine; Duke Clinical Research Institute—Director</td>
<td>• Boehringer Ingelheim</td>
<td>• Genentech</td>
<td>• Janssen Pharmaceuticals</td>
<td>• Johnson &amp; Johnson</td>
<td>• Merck</td>
<td>• Eli Lilly†</td>
<td>DCRI has numerous grants and contracts sponsored by industry that are relevant to the content of this CPG. Dr. Peterson participated in discussions but recused himself from writing or voting, in accordance with ACC/AHA policy. See comprehensive RWI table for a complete list of companies pertaining to this organization.</td>
</tr>
<tr>
<td>Marc S. Sabatine</td>
<td>Brigham and Women’s Hospital, Chairman—TIMI Study Group, Division of Cardiovascular Medicine; Harvard Medical School—Professor of Medicine</td>
<td>• Amgen</td>
<td>• AstraZeneca</td>
<td>• Bristol-Myers Squibb</td>
<td>• Merck</td>
<td>• Pfizer</td>
<td>• Sanofi-aventis</td>
<td>• Abbott Laboratories†</td>
</tr>
</tbody>
</table>
# Amsterdam EA, et al.
## 2014 AHA/ACC NSTE-ACS Executive Summary

<table>
<thead>
<tr>
<th>Member</th>
<th>Affiliation</th>
<th>Relationships</th>
<th>Significant Interests</th>
<th>Significant Interests</th>
<th>Significant Interests</th>
<th>Significant Interests</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard W. Smalling</td>
<td>University of Texas, Health Science Center at Houston—Professor and Director of Interventional Cardiovascular Medicine; James D. Woods Distinguished Chair in Cardiovascular Medicine</td>
<td>Gilead, Maquet</td>
<td>None</td>
<td>None</td>
<td>Cordis, E-valve Abbott Vascular, Edwards Lifesciences, Gilead, Maquet Datascope</td>
<td>None</td>
</tr>
<tr>
<td>Susan J. Zieman</td>
<td>National Institute on Aging/NIH, Geriatrics Branch, Division of Geriatrics and Clinical Gerontology—Medical Officer</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the GWC during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$10,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted.

According to the ACC/AHA, a person has a relevant relationship IF: a) the relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document, or makes a competing drug or device addressed in the document; or c) the person or a member of the person’s household, has a reasonable potential for financial, professional or other personal gain or loss as a result of the issues/content addressed in the document.

*Writing members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply. Section numbers pertain to those in the full-text CPG.*


Appendix 2. Reviewer Relationships With Industry and Other Entities (Relevant)—2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes

<table>
<thead>
<tr>
<th>Reviewer</th>
<th>Representation</th>
<th>Employment</th>
<th>Consultant</th>
<th>Speakers Bureau</th>
<th>Ownership/Partnership/Principal</th>
<th>Personal Research</th>
<th>Institutional, Organizational, or Other Financial Benefit</th>
<th>Expert Witness</th>
</tr>
</thead>
</table>
| Deepak L. Bhatt     | Official Reviewer—AHA | VA Boston Healthcare System—Professor of Medicine, Harvard Medical School; Chief of Cardiology | • BMS/Pfizer  
• DCRI  
(BMS/Pfizer)  
• DCRI (Eli Lilly)  
• Eli Lilly | None | None | None | None | AstraZeneca*  
• Bristol-Myers Squibb*  
• Ethicon*  
• The Medicines Company  
• Medtronic*  
• Sanofi-aventis*  
• Takeda† | Medscape Cardiology (Advisory Board) †  
WebMD (Steering Committee)† | None |
| John E. Brush, Jr   | Official Reviewer—ACC Board of Trustees | Eastern Virginia Medical School—Professor of Medicine, Chief of Cardiology | None | None | None | None | None | None |
| E. Magnus Ohman     | Official Reviewer—ACC/AHA Task Force on Practice Guidelines | Duke Medicine—Professor of Medicine | • AstraZeneca  
• Bristol-Myers Squibb  
• Gilead*  
• Janssen Pharmaceuticals*  
• The Medicines Company  
• Merck  
• Pozen  
• Roche  
• Sanofi-aventis | None | None | None | None | Daiichi-Sankyo*  
• Eli Lilly*  
• Gilead* | None | None |

†Significant relationship.
‡No financial benefit.

ACC indicates American College of Cardiology, AHA, American Heart Association, BMS, Bristol-Myers Squibb; CPG, clinical practice guideline; DCRI, Duke Clinical Research Institute; NIH, National Institutes of Health; NYU, New York University; RWI, relationships with industry and other entities; TIMI, Thrombolysis In Myocardial Infarction; and VA, Veterans Affairs.
<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Institution/Position</th>
<th>Company/Institution</th>
<th>Relationship/Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>John F. Robb</td>
<td>Official Reviewer—ACC Board</td>
<td>Dartmouth-Hitchcock Medical Center—Director, Interventional Cardiology and Cardiac Catheterization Laboratories</td>
<td>None</td>
<td>Defendant, adverse drug reaction, 2012</td>
</tr>
<tr>
<td>Sarah A. Spinler</td>
<td>Official Reviewer—AHA</td>
<td>Philadelphia College of Pharmacy, University of the Sciences in Philadelphia—Professor of Clinical Pharmacy</td>
<td>None</td>
<td>Plaintiff, clopidogrel, 2013</td>
</tr>
<tr>
<td>Gorav Ailawadi</td>
<td>Organizational Reviewer—STS</td>
<td>University of Virginia Health System—Thoracic and Cardiovascular Surgery</td>
<td>• Bristol-Myers Squibb</td>
<td></td>
</tr>
<tr>
<td>Srijhari S. Naidu</td>
<td>Organizational Reviewer—SCAI</td>
<td>Winthrop University Hospital—Director, Cardiac Catheterization Laboratory</td>
<td>• Abbott</td>
<td></td>
</tr>
<tr>
<td>Robert L. Rich, Jr.</td>
<td>Organizational Reviewer—AAFP</td>
<td>Bladen Medical Associates—Family Physician</td>
<td>• Atricure</td>
<td></td>
</tr>
<tr>
<td>Mouaz H. Al-Mallah</td>
<td>Content Reviewer—ACC</td>
<td>King Abdul-Aziz Cardiac Center—Associate Professor of Medicine</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>John A. Ambrose</td>
<td>Content Reviewer</td>
<td>University of California San Francisco Fresno Department of Medicine—Professor of Medicine; Chief of</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Role</td>
<td>Institution/Position</td>
<td>Sponsors</td>
<td></td>
</tr>
<tr>
<td>-----------------------------</td>
<td>------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Giuseppe Ambrosio</td>
<td>Content Reviewer—ACC</td>
<td>University of Perugia School of Medicine—Medical Director, Division of Cardiology</td>
<td>§ Bayer* § The Medicines Company § Merck Schering-Plough § Pfizer § Sanofi-aventis</td>
<td></td>
</tr>
<tr>
<td>H. Vernon Anderson</td>
<td>Content Reviewer</td>
<td>University of Texas—Professor of Medicine</td>
<td>§ Eli Lilly</td>
<td></td>
</tr>
<tr>
<td>Jeffrey L. Anderson</td>
<td>Content Reviewer—ACC/AHA Task Force on Practice Guidelines</td>
<td>Intermountain Medical Center—Associate Chief of Cardiology</td>
<td>§ Sanofi-aventis § GlaxoSmithKline § Harvard (DSMB)—TIMI-48, -51, and -54Studies</td>
<td></td>
</tr>
<tr>
<td>Fred S. Apple</td>
<td>Content Reviewer</td>
<td>University of Minnesota School of Medicine—Associate Professor, Laboratory Medicine and Pathology</td>
<td>§ Abbott Diagnostics § Alere § Beckman Coulter § T2 Biosystems § Abbott Diagnostics—PI § Alere—PI § Ortho-Clinical Diagnostics—PI</td>
<td></td>
</tr>
<tr>
<td>Emmanouil S. Brilakis</td>
<td>Content Reviewer—ACC Intervventional Section Leadership Council</td>
<td>UT Southwestern Medical School—Director, Cardiac Catheterization Laboratory, VA North Texas Healthcare System</td>
<td>§ Bridgepoint Medical/Boston Scientific § Janssen Pharmaceuticals § Sanofi-aventis</td>
<td></td>
</tr>
<tr>
<td>Matthew J. Budoff</td>
<td>Content Reviewer—ACC Cardiovascular</td>
<td>Los Angeles Biomedical Research Institute—Program Director, Division of</td>
<td>§ AstraZeneca § General Electric § Plaintiff, cardiac treatment, 2013</td>
<td></td>
</tr>
</tbody>
</table>
### Imaging Section Leadership Council

<table>
<thead>
<tr>
<th>Name</th>
<th>Content Reviewer—ACC Section Leadership Council</th>
<th>University of Maryland School of Medicine—Professor of Pathology; Professor of Medical and Research Technology; Director, Rapid Response Laboratory</th>
<th>None</th>
<th>None</th>
<th>None</th>
<th>None</th>
<th>None</th>
<th>None</th>
</tr>
</thead>
<tbody>
<tr>
<td>James A. Burke</td>
<td>Content Reviewer—ACC Interventional Section Leadership Council</td>
<td>Lehigh Valley Health Network—Interventional Cardiologist</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Robert H. Christenson</td>
<td>Content Reviewer—AACC Interventional Section Leadership Council</td>
<td>University of Maryland School of Medicine—Professor of Pathology; Professor of Medical and Research Technology; Director, Rapid Response Laboratory</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Joaquin E. Cigarroa</td>
<td>Content Reviewer—ACC Interventional Section Leadership Council</td>
<td>Oregon Health and Science University—Associate Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Marco A. Costa</td>
<td>Content Reviewer—ACC Cardiovascular Imaging Section Leadership Council</td>
<td>University Hospital for Cleveland—Cardiologist</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Prakash C. Deedwania</td>
<td>Content Reviewer—ACC Interventional Section Leadership Council</td>
<td>University of California San Francisco—Chief of Catheterization and Cardiovascular Intervention (Editorial Board)</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

### Cardiology and Professor of Medicine

- **BG Medicine**
- **Critical Diagnostics**
- **Siemens Medical Diagnostics**
- **AACC (President) †**
- **Roche Diagnostics (University of Maryland School of Medicine)*
- **Catheterization and Cardiovascular Intervention (Editorial Board) †**
- **Abbott Vascular***
- **Boston Scientific**
- **Cordis***
- **IDEV Technology†**
- **The Medicines Company**
- **Medtronic**
- **Micell*”
- **OrbusNeich†**
- **Abbott**
- **Cordis**
- **Medtronic**
- **Amgen**
- **Pfizer**
- **Pfizer**
- **Takeda Pharmaceuticals**
Amsterdam EA, et al.
2014 AHA/ACC NSTE-ACS Executive Summary

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Institution</th>
<th>Affiliations</th>
<th>Conflicts</th>
</tr>
</thead>
<tbody>
<tr>
<td>James A. de Lemos</td>
<td>Content Reviewer</td>
<td>UT Southwestern Medical School—Associate Professor of Medicine; Director, Coronary Care Unit and Cardiology Fellowship</td>
<td>• Diadexus • Janssen Pharmaceuticals • AstraZeneca</td>
<td>• Abbott Diagnostics† • Daiichi-Sankyo† None</td>
</tr>
<tr>
<td>Burl R. Don</td>
<td>Content Reviewer</td>
<td>University of California Davis—Professor of Medicine; Director of Clinical Nephrology</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Lee A. Fleisher</td>
<td>Content Reviewer</td>
<td>University of Pennsylvania Department of Anesthesiology—Professor of Anesthesiology</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Mary G. George</td>
<td>Content Reviewer—HHS</td>
<td>Centers for Disease Control and Prevention—Senior Medical Officer, Division for Heart Disease and Stroke Prevention</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Linda D. Gillam</td>
<td>Content Reviewer—ACC</td>
<td>Morristown Medical Center—Professor of Cardiology; Vice Chair, Cardiovascular Medicine</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Robert A. Guyton</td>
<td>Content Reviewer—ACC/AHA</td>
<td>Emory Clinic—Professor and Chief, Division of</td>
<td>• Medtronic†</td>
<td>None</td>
</tr>
</tbody>
</table>
### Amsterdam EA, et al.
#### 2014 AHA/ACC NSTE-ACS Executive Summary

<table>
<thead>
<tr>
<th>Task Force on Practice Guidelines</th>
<th>Cardiothoracic Surgery</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joerg Herrmann</td>
<td>None</td>
</tr>
<tr>
<td>Content Reviewer—ACC Interventional Section Leadership Council</td>
<td>None</td>
</tr>
<tr>
<td>Mayo Medical School—Internal Medicine and Cardiovascular Disease</td>
<td>None</td>
</tr>
<tr>
<td>Judith S. Hochman</td>
<td>None</td>
</tr>
<tr>
<td>Content Reviewer—ACC/AHA Task Force on Practice Guidelines</td>
<td>None</td>
</tr>
<tr>
<td>New York University School of Medicine, Division of Cardiology—Clinical Chief of Cardiology</td>
<td>None</td>
</tr>
<tr>
<td>Yuling Hong</td>
<td>None</td>
</tr>
<tr>
<td>Content Reviewer—HHS</td>
<td>None</td>
</tr>
<tr>
<td>Centers for Disease Control and Prevention—Associate Director</td>
<td>None</td>
</tr>
<tr>
<td>Lloyd W. Klein</td>
<td>None</td>
</tr>
<tr>
<td>Content Reviewer—ACC Interventional Section Leadership Council</td>
<td>None</td>
</tr>
<tr>
<td>Rush Medical College—Professor of Medicine</td>
<td>None</td>
</tr>
<tr>
<td>Frederick G. Kushner</td>
<td>None</td>
</tr>
<tr>
<td>Content Reviewer</td>
<td>None</td>
</tr>
<tr>
<td>Tulane University School of Medicine—Clinical Professor of Medicine; Heart Clinic of Louisiana—Medical Director</td>
<td>None</td>
</tr>
<tr>
<td>Ehtisham Mahmud</td>
<td>None</td>
</tr>
<tr>
<td>Content Reviewer—ACC Interventional Section Leadership Council</td>
<td>None</td>
</tr>
<tr>
<td>University of California, San Diego—Professor of Medicine/Cardiology, Chief of Cardiovascular Medicine; Director,</td>
<td>None</td>
</tr>
<tr>
<td>• Abiomed</td>
<td></td>
</tr>
<tr>
<td>• Cordis†</td>
<td></td>
</tr>
<tr>
<td>• Eli Lilly</td>
<td></td>
</tr>
<tr>
<td>• Gilead</td>
<td></td>
</tr>
<tr>
<td>• Johnson &amp; Johnson</td>
<td></td>
</tr>
<tr>
<td>• Medtronic</td>
<td></td>
</tr>
<tr>
<td>• Eli Lilly*</td>
<td></td>
</tr>
<tr>
<td>• Medtronic</td>
<td></td>
</tr>
<tr>
<td>• Abbott Vascular*</td>
<td></td>
</tr>
<tr>
<td>• Accumetrics*</td>
<td></td>
</tr>
<tr>
<td>• Merck Schering—Plough</td>
<td></td>
</tr>
<tr>
<td>• Boston Scientific*</td>
<td></td>
</tr>
<tr>
<td>• Gilead*</td>
<td></td>
</tr>
<tr>
<td>• The Medicines</td>
<td></td>
</tr>
</tbody>
</table>

Page 51 of 70
## Interventional Cardiology and Cardiovascular Catheterization Laboratory

<table>
<thead>
<tr>
<th>Name</th>
<th>Company</th>
<th>Content Reviewer—ACC Heart Failure and Transplant Section Leadership Council</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carlos Martínez-Sánchez</td>
<td>Sanofi-aventis*</td>
<td></td>
</tr>
<tr>
<td>L. Kristen Newby</td>
<td>AstraZeneca†</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Eli Lilly†</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sanofi-aventis†</td>
<td></td>
</tr>
<tr>
<td>Patrick T. O’Gara</td>
<td>Amylin</td>
<td></td>
</tr>
<tr>
<td></td>
<td>AstraZeneca</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bristol-Myers Squibb*</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Eli Lilly</td>
<td></td>
</tr>
<tr>
<td></td>
<td>GlaxoSmithKline</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Merck*</td>
<td></td>
</tr>
<tr>
<td>Narith Ou</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gurusher S. Panjrath</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rajan Patel</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Interventional Cardiology and Cardiovascular Catheterization Laboratory**

**Company**

- Sanofi-aventis*
- AstraZeneca†
- Eli Lilly†
- Sanofi-aventis†
- Amylin
- AstraZeneca
- Bristol-Myers Squibb*
- Eli Lilly
- GlaxoSmithKline
- Merck*

---

**Content Reviewer—ACC Heart Failure and Transplant Section Leadership Council**

- Carlos Martínez-Sánchez
- L. Kristen Newby
- Patrick T. O’Gara
- Narith Ou
- Gurusher S. Panjrath
- Rajan Patel
Amsterdam EA, et al.
2014 AHA/ACC NSTE-ACS Executive Summary

<table>
<thead>
<tr>
<th>Leadership Council</th>
<th>Content Reviewer</th>
<th>Institutions and Roles</th>
<th>AstraZeneca</th>
<th>Gilead Sciences</th>
<th>Pfizer</th>
<th>Sanofi-aventis</th>
<th>Abbott Vascular</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carl J. Pepine</td>
<td>Content Reviewer</td>
<td>Shands Hospital at University of Florida—Professor and Chief, Division of Cardiovascular Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Sunil V. Rao</td>
<td>Content Reviewer—ACC Interventional Section Leadership Council</td>
<td>Duke University Medical Center—Associate Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Pasala S. Ravichandr an</td>
<td>Content Reviewer—ACC Surgeons’ Scientific Council</td>
<td>Oregon Health and Science University—Associate Professor</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Michael W. Rich</td>
<td>Content Reviewer</td>
<td>Washington University School of Medicine—Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Frank W. Sellke</td>
<td>Content Reviewer—ACC/AHA Task Force on Practice Guidelines</td>
<td>Brown Medical School, Rhode Island Hospital—Professor, Chief of Cardiothoracic Surgery</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Alan Wu</td>
<td>Content Reviewer—AACC</td>
<td>San Francisco General Hospital and Trauma Center—Chief, Clinical Chemistry Laboratory</td>
<td>Abbott</td>
<td>Singulex</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

This table represents the relationships of reviewers with industry and other entities that were disclosed at the time of peer review and determined to be relevant to this document. It does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$10,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. A relationship is considered to be modest if it is less than.
significant under the preceding definition. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within each category of review.

According to the ACC/AHA, a person has a relevant relationship IF: a) the relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document, or makes a competing drug or device addressed in the document; or c) the person or a member of the person’s household, has a reasonable potential for financial, professional or other personal gain or loss as a result of the issues/content addressed in the document.

*Significant relationship.
†No financial benefit.

AAAHC indicates Accreditation Association for Ambulatory Health Care; AACC, American Association for Clinical Chemistry; AAFP, American Academy of Family Physicians; AHA, American Heart Association; AIG, Association of International Governors; BMS, Bristol-Myers Squibb; DCRI, Duke Clinical Research Institute; DSMB, data safety monitoring board; HHS, Health and Human Services; NHLBI, National Heart, Lung, and Blood Institute; NIH, National Institutes of Health; SCAI, Society for Cardiovascular Angiography and Interventions; STS, Society of Thoracic Surgeons; TIMI, Thrombolysis In Myocardial Infarction; and VA, Veterans Affairs.
References

Amsterdam EA, et al.  
2014 AHA/ACC NSTE-ACS Executive Summary


Amsterdam EA, et al.  
2014 AHA/ACC NSTE-ACS Executive Summary


Amsterdam EA, et al. 2014 AHA/ACC NSTE-ACS Executive Summary

Amsterdam EA, et al.
2014 AHA/ACC NSTE-ACS Executive Summary


Amsterdam EA, et al.
2014 AHA/ACC NSTE-ACS Executive Summary


Page 63 of 70


Amsterdam EA, et al.
2014 AHA/ACC NSTE-ACS Executive Summary


Amsterdam EA, et al.
2014 AHA/ACC NSTE-ACS Executive Summary


Page 66 of 70


Amsterdam EA, et al.  
2014 AHA/ACC NSTE-ACS Executive Summary


Amsterdam EA, et al.  
2014 AHA/ACC NSTE-ACS Executive Summary


